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Pancreatic cancer (PC) remains a significant, unresolved issue because of its complex 
genetic blueprint and lack of reliable detection markers. The purpose of this study was to 
examine the possible correlation between tobacco use, gender, and age in the 
etiopathogenesis of PC and other cancer types with a shared-gene association (CTSG-A). 
The unified paradigm of cancer causation was used to understand the pathopoiesis 
mechanism of smoking and shared genes in PC. A cross-sectional study was performed 
using secondary data from the cancer survivorship module of the 2014 Behavioral Risk 
Factor Surveillance System survey. Results of ordinal logistic regression analyses 
indicated no correlation between smoking and prevalence of PC and CTSG-A, but gender 
and age were significant predictors. Gender has a statistically significant effect on the 
prediction of PC/ CTSG-A induction and promotion. Increased probability of developing 
the disease was found as the person reach the age between 62 and 69 years of age. 
Findings may enhance the understanding of environmental, genetic, and biodemographic 
interactions in disease evolution (induction, promotion, and expression periods). Findings 
may also be used to promote population health and improve health behaviors for 
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A night before my youngest brother passed away, he said, “Promise me that you 
will go back to school, and someday take on a research project that could make a 
difference to individuals diagnosed with this very painful disease.” He passed away in 
2007 of pancreatic cancer, a few weeks before his 40th birthday, and 3 months before the 
first birthday of his only daughter. In December 2012, as a promise to my brother, I 
enrolled in the Public Health Ph.D. program specializing in epidemiology. When a sad or 
tragic event happens, we have three choices. We can let this event define us, let it destroy 
us, or let it strengthen us. For somebody who is over 50 years old like me, going back to 
school is sometimes misconstrued as a dream too high to reach. To be given an equal 
chance to have a better education is not about to a sense of pride, but about making a 
difference for others who have nothing but hope. The courage to face any obstacles is an 
important component of positive social change.  
In Texas, we believe in winning big as the American dream. My dream is that 
everyone, not just my family and me, will have a better understanding of the complexity 
of pancreatic carcinogenesis after reading this dissertation. Words cannot express my 
gratitude and love throughout this journey. I would like to dedicate this dissertation to my 
brother, Rey; his daughter, Leighna; my daughter, Abigail; and my boys, Reighben, 




I started this journey by listening to the iTunesU Public Health 241 Spring 2012 
lectures by Dr. Nicholas P. Jewell of UC Berkeley. Many people have contributed to this 
dissertation, and I owe them my sincere gratitude for making this endeavor possible. I 
would like to thank Dr. Precilla Belin for her guidance, understanding, and patience 
during this process. She encouraged me to grow as scholar/practitioner, and she placed an 
indelible mark on my intellectual development. I would also like to thank my former 
professor, Dr. Wen-Hung Kuo, who was a member of my committee for his input, 
valuable discussions, accessibility, and mentorship since 2013. The insightful comments 
and constructive criticisms of Dr. LaToya Johnson, who served in the role of university 
reviewer, helped me focus on my ideas. No one can achieve their dreams alone. I have 
the strength that my daughter provided, as well as the sparks of knowledge I got from Dr. 
Jewell and the scholarly footprints of researchers who helped me shape this dissertation 
and justified the positive social change that could enhance the quality of life for those 
fighting pancreatic cancer. Lastly, I would like to acknowledge President Barack Obama 
who reminded me that there is always hope. On his letter dated June 16, 2016, he noted 
how the experience we share in experiencing grief and hardship of losing a family 
member made him forge a future free from cancer in all its forms. He highlighted the 
mission statement of the Moonshot initiative in accelerating progress toward prevention, 
treatment, and cure to spare more people the heartbreak cancer causes. 
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Chapter 1: Introduction to the Study 
To raise new questions, new possibilities, to regard old problems from a new 
angle requires creative imagination and marks the real advance in science (Einstein & 
Infeld, 1938, p. 92). Pancreatic cancer (PC) at the start of the 21st century continues to be 
a vital unresolved health problem, remaining as one of the deadliest human cancers. 
Although genetic changes can be either somatic or hereditary, described as de novo 
(new), PC does not arise de novo (Maitra & Hruban, 2008), but rather initiated by a 
probable gene mutation such as p16/CDKN2A that results to debilitating metabolic 
effects of uncontrolled growth. The five-year survival rate of less than 5% of PC is a 
statistic that remains constant for many years (Garcia et al., 2007; Hidalgo, 2010; 
Makohon-Moore, Brosnan, & Iacobuzio-Donahue, 2013). Hoeijmakers (2009) stated that 
the damage to the DNA is the causality of the development of PC, and continued inquiry 
is paramount to understand the principles of its cancer biology. Zakharova, 
Karmazanovsky, and Egorov (2012) found that the minor populations of cells with stem-
like properties had been identified and appear responsible for the development and 
progression of pancreatic cancer. According to Hruban Canto, Goggins, Schulick, and 
Klein (2010), although some of the aggregation of PC arises from environmental factors 
such as tobacco use, aggregation of the disease in families could be due to chance and 
genetics.  
There are three ways that DNA can be mutated: inherited mutation in the context 
of genetic predisposition or susceptibility, DNA mutation caused by behavioral risk 
factors, and DNA damaged by chance (Couch et al., 2007; Irigaray et al., 2007; Jones et 
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al., 2009). Even if an individual has an inherited syndrome or inherited predisposition, a 
person with one good copy of the cancer-associated gene may or may not develop the 
disease (Suter, 2015). Given the assumption that a disease is caused by a factor that can 
be controlled, exploring the relationship between modifiable health behaviors such as 
smoking and family cancer history (FCH), cancer predisposition genes (CPG) or shared 
genes was a legitimate endeavor. In this study, genetic syndromes associated with PC 
were interchangeably referred to as FCH, CPG, or shared genes. Understanding of the 
biology of PC has progressed over the years, including advances in patient management. 
According to Vincent, Herman, Schulick, Hruban, and Goggins (2011), the evidence is 
starting to show that first-degree screening relatives of individuals with several family 
members affected by PC can identify noninvasive precursors of this lethal disease. 
Vincent et al. demonstrated the incidence of and the number of deaths caused by 
pancreatic tumors had been gradually rising, even as incidence and mortality of other 
common cancers have been declining. The poor response to most chemotherapeutic 
agents among patients with advanced unresectable PC (Vincent et al., 2011) highlights 
the need for more effective control of tumor initiation and metastasis, and for a better 
understanding of the evolutionary framework of the disease.  
Exploring the Darwinian nature of PC could lead to improvement in conventional 
therapies. Vincent et al. (2011) justified the significance of understanding the biological 
mechanisms contributing to the development and progression of pancreatic tumors. Klein 
et al. (2004) highlighted the importance of quantification of the risk of individuals with 
shared genes as a basis for cancer risk screening and counseling. In this cross-sectional 
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study, the quantification of PC risk among Behavioral Risk Factor Surveillance Survey 
(BRFSS) participants diagnosed with the disease supported the assumption of increased 
risk in association with shared genes and shared environmental factors such as smoking. 
Given Blackford et al.’s (2009) findings regarding the nonspecific DNA damage caused 
by tobacco carcinogens, I examined the correlation between tobacco carcinogen-related 
mutations, inherited cancer predisposition, and new cases of pancreatic cancer. The social 
change implications of this study depended on the success of quantifying the association 
between smoking and CPG, highlighting the importance of tobacco-use cessation as a 
lifestyle and health-enhancing behavioral change. Although findings may not have 
indicated an association between tobacco use and CPG in the development and 
progression of PC, including gender and age, the study amplified the need for smoking 
cessation programs and cancer-specific profiles.  
Background 
Tersmette et al. (2001) and Reznik, Hendifar, and Tuli (2015) examined the risk 
of developing PC among first-degree relatives in families with the disease using the 
National Familial Pancreas Tumor Registry (NFPTR). Hruban et al. (2010) confirm the 
elevated risk level of both pancreatic and extrapancreatic malignancies to individuals 
with a family history of PC. Although the genetic basis of more than 80% of the 
clustering of pancreatic cancer in families remains unknown, Hruban et al. addressed the 
significance of the resultant flood of information that could be generated by investigators 
at Johns Hopkins University in sequencing candidate familial pancreatic cancer genes. 
The findings strengthened the NFPTR through aggregation of data from international 
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screening and surveillance by a consortium of 25 countries. Likewise, the 2013 study by 
Canto et al. supported the importance of screening, surveillance, and management of 
high-risk individuals with an inherited predisposition to PC. Reznik et al. (2015) also 
discussed the future directions and usefulness of screening for individuals with familial 
pancreatic cancer. Similarly, Bartsch, Gress, and Langer (2012); Brand et al. (2007); 
Canto et al. (2013); and Klein (2012) discussed the practicality of screening swirled on 
individuals who are carriers of a mutation in an established high-penetrance pancreatic 
ductal adenocarcinoma (PDAC) susceptible genes—BRCA2 (BReast CAncer gene two) 
and PALB2 (Partner and Localizer of BRCA2). 
Prokopczyk et al. (2002) and Ding et al. (2008) investigated the combined 
causality of non-tobacco-related mutagenic risk factors such as the inherited 
predisposition to cancer that may share mutagenic properties with the tobacco mutagens. 
Debates over the current knowledge of modifiable risk factors, such as smoking, tend to 
dominate in the likelihood of increased probability of developing the disease. Schulte et 
al. (2014) elaborated the smoking component primarily relevant to pancreatic cancer risk 
(PCR). After analyzing data from the Queensland Pancreatic Cancer Study, the result 
provided the evidence that in addition to dose effect of tobacco use, the smoking pattern 
may affect PCR. The body of knowledge given by these researchers justifies the purpose 
of this dissertation in examining the association between smoking and the initiation and 
progression of the disease in an individual with FCH. Breitkopf et al. (2012) confirmed 
the importance of addressing behavioral and genetic risk factors for PC, parallel to the 
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association of gender and age, supporting the value of this dissertation in addressing the 
dearth of existing data on the etiopathogenesis of the disease. 
Current State of Understanding 
The pancreatic cancer putative cell of origin remains elusive despite the 
progressive increase in the understanding of pancreatic carcinogenesis from intensive 
histologic and genomic research (Maitra & Hruban, 2008). Patients diagnosed with PC 
stay asymptomatic until the progression of the disease propelled at an advanced stage, 
making PC stand out among the most lethal malignancies (Braat, Bruno, Kuipers, & 
Peppelenbosch 2012; Siegel, Naishadham, & Jemal, 2012). Moreover, this disease often 
mimics other benign conditions, making this disease one of the most challenging cancers 
to detect and treat (Lowenfels & Maisonneuve, 2006). Tobacco use remains the most 
well-established risk factor for PC (Maisonneuve & Lowenfels, 2015), and since the 
1970s, smoking cessation has become the primary tool for reducing the risk of the 
disease. From 2008 to the present, investigators such as Petersen et al. (2010) focused on 
mapping the pancreatic cancer genome and identified common susceptibility loci for PC 
that warrant follow-up studies. The primary reasons behind poor prognosis are early 
metastasis, chemo resistance, and late clinical outcomes, making PC the fourth leading 
cause of cancer-related death globally (Malhotra, Ahn, & Bloomston, 2015). Given the 
heterogeneous nature of PC etiology with an extensive variety of modifications (Thomas 
et al., 2014), the pancreatic tumor genome sequencing provides a path-breaking 
opportunity in mapping smoking-related mutational patterns.  
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Accumulating evidence indicated that carcinogenic tobacco compound 
contributes to the development of pancreatic cancer (Pandol, Apte, Wilson, Gukovskaya, 
& Edderkaoui, 2012). Blackford et al. (2009) argued that smokers could develop a bigger 
number of mutations than nonsmokers, doubling the risks that record for 20 to 25% of 
pancreatic cancers. The types and mutational patterns observed among smokers in 
Blackford et al.’s study gave additional insights on the pathopoiesis component by which 
cigarette smoking causes PC induction and promotion. Parallel to Blackford et al.’s 
conclusion on the impact of tobacco use in increasing the risk of pancreatic growth 
through components other than genetic mutations, Porta et al. (2009) found that tobacco 
smoking increases the risk of PC through events other than Kras mutations. After the 
researchers had evaluated all of the available types of epidemiological and clinical studies 
on the occurrence of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
mutations in human adenocarcinomas in correlation to smoking, the results supported the 
hypothesis that tobacco use influences the risk of PC.  
Problem Statement 
Pancreatic cancer has been estimated to have higher mortality rates, with an 
economic encumbrance of $4.9 billion annually (Pandol et al., 2012). The prognosis of 
pancreatic cancer remains dismal despite the substantial progress in the understanding of 
PC biology. Germline mutation makes up 5% to 10% of all cancers, and of the germline 
gene mutations that have been identified to increase PC risk, mutations in BRCA2 
account for up to 17% of familial pancreatic cancer (FPC) kindreds (Murphy et al., 2002; 
Hahn et al., 2003; Couch et al., 2007). As genomic sequencing technologies have 
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decreased in cost and become more commonplace, there has been much to learn 
regarding differential sensitivities of various DNA damage response (DDR) gene 
mutations, such as somatic versus germline and new mechanisms of treatment resistance 
(Carnevale & Ashworth, 2015). Although genetics may play a role in disease 
development, the procarcinogenic effect of smoking is considered the precursor to the 
development and progression of pancreatic cancer according to Vincent et al. (2011). 
Both Blackford et al. (2009) and Schulte et al. (2014) highlighted the association of 
smoking pattern in the increased risk of the disease. Although Schulte et al. confirmed the 
magnitude of dose effect of smoking to the disease, Blackford et al. failed to establish a 
characteristic profile of the number of tobacco carcinogen-related mutations within the 
pancreas (tail vs. head), tumor grade, patient’s age, sex, margin status, and stage. 
Although the treatment combinations of surgery, radiotherapy, and chemotherapy could 
improve the chance of survival and quality of life, continued research in establishing a 
unique pattern on the pathobiology of PC malignancy among patients who have a history 
of smoking and shared genes is warranted. 
Given the evidence that PC, like most human cancers, contains multiple 
mutations, continued research is needed to advance the understanding of the essential 
principles of its cancer biology (Hoeijmakers, 2009). Although the Darwinian nature of 
PC makes the prediction of its evolution virtually impossible (Lennon et al., 2014), 
smoking often has a multiplicative increase in PC risk when combined with other risk 
factors such as alcohol, recent onset diabetes, and family history (Jansen, Tan, & 
Petersen, 2015; Schenk et al., 2001). Carcinogens from tobacco such as N-nitrosamines, 
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benzo(a)pyrene, polycyclic aromatic hydrocarbons, A-napthylamine, 
methylfluoranthenes, and arylamines are capable of forming DNA adducts that increase 
the risk of somatic mutations and PC (Jansen et al., 2015; Suwan-ampai, Navas-Acien, 
Strickland, & Agnew, 2009; Vrieling et al., 2010). In addition to an increasing amount of 
research regarding dynamic epigenetic processes and their role in gene regulation (Jansen 
et al., 2015), past and present epidemiologic studies such as Yang et al. (2012) indicated 
a significant interaction between smoking and cytotoxic T-lymphocyte-associated protein 
on the risk of PC.  
Jansen et al. (2015) underscored the significance of genetic data that can assist in 
identifying individuals at high risk of developing PC, which confirms the need for new 
statistical and epidemiological methods to pinpoint the responsible genetic variants and 
their interaction with modifiable risk factors. Tobacco use is a modifiable risk factor that 
has been studied extensively (Iodice, Gandini, Maisonneuve, & Lowenfels, 2008). 
Taking into account the gene-environment interaction with modifiable risk factors such 
as tobacco use is the cogent step to understanding the epidemiology and pathometry of 
PC. The unique contribution of this dissertation to the current body of knowledge 
involved examining the links between tobacco use, gender, age, PC, and shared genes. 
This dissertation could promote population health, and lessons learned could reshape the 
current understanding of cancer epidemiology by providing the scientific justification for 
the implementation of screening, surveillance, and education programs. The outcome of 
this dissertation would fit into the practical intervention approach of adopting a healthy 
lifestyle such as smoking cessation as part of positive, meaningful social change to 
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improve prognosis and quality of life during PC progression. Like the Pancreatic Cancer 
Detection Consortium (PCDC), the principal intent of this dissertation was in response to 
the Recalcitrant Cancer Act, signed into law on January 2, 2013, after strong bipartisan 
support for President Barack Obama. The outcome of this study could support the 21st-
century thinking that underscores the influence of modifiable risk factors in relation to 
healthy lifestyle choices in lowering the risk of developing pancreatic cancer. The 
mechanism through which the role of smoking in augmenting the development or 
accelerating the progression of PC to individuals with FCH, CPG, or shared genes needs 
a well-grounded inquiry for new complementary/alternative research direction that will 
underpin the existing body of knowledge. In response to the need to enhance the 
understanding of PC epidemiology, this dissertation will address the gap in exploring the 
interaction between shared environmental factors (tobacco use) and shared genes, as well 
as the role of gender and age as explanatory variables. 
Purpose of the Study 
PC is a complex and highly lethal disease, best treated in a multidisciplinary 
setting. The grim survival statistics of PC justify the intent of this dissertation to establish 
clarity about the pathopoiesis mechanism of tobacco use and CPG or its combined role in 
the etiopathogenesis of the disease. There are numerous studies on the association of 
relevant risk factors for PC, but there are limited studies linking smoking level to CPG or 
FCH. Schottenfeld and Fraumeni (2006) and Silverman et al. (1994) asserted that 
smoking exhibits its biologic effects on both early and later stages of the carcinogenic 
process. The purpose of this dissertation was to establish clarity on the role of tobacco 
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use in the development of PC among individuals with FCH, cancer predisposition gene 
(CPG), or shared genes. Because the size of the primary lesion has a correlation with 
long-term survival, the innate metastatic propensity of this disease needs further study 
addressing the behavior, prevention, and mechanisms associated with pancreatic cancer 
risk (Chari et al., 2015; Perera & Bardeesy, 2015). Although it is important to treat a 
complex and highly lethal disease like PC in a multidisciplinary setting, Wolfgang et al. 
(2013) asserted that the prevention of an invasive PC is dependent on the improvements 
in the management of cystic pancreatic lesions. 
Research Questions 
Pancreatic cancer and other cancers found to have a shared-gene association (S-
GA) were the dependent variables, and smoking status, age, and gender were the 
independent variables; this study addressed the following research questions (RQs) and 
hypotheses: 
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic 
cancer and cancer types with shared gene association (CTSG-A)? 
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.  
H1: Smoking can increase the risk of PC and CTSG-A. 
RQ2: Is there a relationship between the combined role of age and gender in the 
etiopathogenesis of PC and CTSG-A? 
H02: Age and gender have no correlation with prevalence of PC and CTSG-A. 
H2: Age and gender are correlated with the prevalence of PC and CTSG-A. 
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Chapter 3 provides a more detailed discussion of the objectives, research questions, 
hypotheses, and analysis plan. 
Theoretical Basis for the Study 
To properly frame the hypothesis that tobacco use, gender, and age in 
combination with inherited mutation could increase the risk of developing PC and CTS-
GA, a metatheory was appropriate to unriddle the axiom of biologic synergism and the 
link of a causal modifiable risk factor. Based on Rothman’s (1986) notion of 
epidemiologic interaction, the biologic synergism explored in this dissertation was the 
sufficient cause of tobacco use (A) and cancer predisposition gene or FCH (B); if both 
are present, there is an increased risk of PC. Although the sufficient cause paradigm 
could also help support a working hypothesis that individuals with inherited mutations 
have a higher risk for the disease without A, the presence of A or act in combination with 
B could mean a probable higher cause of malignancy. On the other hand, removal of A 
implies that the probable additional mutations caused by exposure to A could eliminate 
the sufficient cause of A in the etiopathogenesis pathopoiesis (see Figure 1).  
Knudson’s two-hit theory of cancer causation may be appropriate in explaining 
the pathopoiesis mechanism involved in FCH. However, the Unified Paradigm of Cancer 
Causation (UPCC) as the proposed metatheory in this dissertation could provide 
arguments on the positive association (synergism) between tobacco use and FCH, giving 
more clarity to Rothman’s notion of epidemiologic interaction or the paradigm of 
sufficient cause. UPCC is a composite construct of the germ theory and the somatic 
mutation theory of carcinogenesis (SMT) in combination with the traditional or 
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Darwinian evolutionary system (Greaves & Maley, 2012), Knudson’s two-hit theory 
(Hermanowicz, 2015), genome theory, Darwinian theory of social change (Richerson & 
Boyd, 2000), and the multi-level biologic, social integrative construct (MBASIC). The 
theoretical cocktail of UPCC could interlock new insights on tumor initiation, metastases 
diagnostic, and treatment strategies.  
 
Figure 1. Component cause model for the causes of hypothetical pathopoiesis mechanism 
of smoking and family cancer history in the etiopathogenesis of pancreatic cancer. 
 
The germ theory of disease of the 20th century needs to be in the context of 21st 
century medicine (Whitcomb, 2014) and part of a metatheory that will classify patients 
based on a risk factor or a combination of factors (e.g., smoking, gender, age) that could 
contribute to the existing knowledge of PC etiology rather than its symptoms and 
complications. Although traditional evolutionary theory could help the understanding of 
pancreatic tumor growth at the molecular level (Aktipis, Boddy, Gatenby, Brown, & 
Maley, 2013), the genome theory of cancer evolution (Vogelstein et al., 2013) could help 
explain the direction of development and pattern of progression of the disease. Cancer of 
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the pancreas is a genetic disease, and MBASIC could help explain its Darwinian 
character and link the correlation of tobacco use and family cancer history. According to 
Lynch and Rebbeck (2013), MBASIC allows researchers from the fields of public health, 
health policy, epidemiology, biology, clinical medicine, prevention, behavioral sciences, 
sociology, and others to test hypotheses of interest. MBASIC aided in the study design, 
guided the development of statistical or mechanistic models to examine the covariates, 
and positioned the results of this study for improved intervention, translation, and 
implementation. 
Nature of the Study 
Assessment of lifetime smoking history selected through random stratification 
from the core sections and cancer survivorship module of the 2014 BRFSS data sets was 
not only a valuable instrument for this study but also for the future development of the 
Expanded BRFSS. The key variables in this dissertation were cancer types from the 
BRFSS cancer survivorship module (outcome), and the core section on tobacco use, 
gender, and age (predictors). The intent of this study was to examine the association 
between smoking, gender, age, PC, and shared genes. Popular study designs are subject 
to various biases that include social desirability, recall, and selection bias. Despite the 
weaknesses of secondary data and cross-sectional studies, multiple outcomes and 
exposures can be explored using a cross-sectional design.  
The argument on the influence of tobacco consumption on individuals with shared 
genes and calculating prevalence proportion, the positive and negative predictive values 
of the regression models were assessed to determine the statistical significance of the 
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independent variables (smoking status, gender, age) in the induction and progression of 
PC. The ordinal logistic model was used to consider possible correlation. Secondary data 
from the 2014 BRFSS were recoded and randomized using the Statistical Package for the 
Social Sciences (SPSS). 
Definitions 
BRCA2: BReast CAncer Gene 2, the tumor suppressor gene associated with 
hereditary predisposition to pancreatic, breast, ovarian, and other cancers (Cassidy, Liau 
& Venkitaraman, 2014). 
Clonal mutation: A mutation that exists in the vast majority of neoplastic cells 
within a tumor (Vogelstein et al., 2013). 
Darwinian model: A theory used to explain that the genetic variation introduced 
continually into the population via stochastic mutational events and that those cell clones 
that happen to acquire alleles conferring proliferative and/or survival advantages become 
overrepresented via a process of purifying selection (Valastyan & Weinberg, 2011). 
De novo: An alteration/mutation in a gene that is present for the first time in one 
family member as a result of a mutation in a germ cell of one of the parents or in the 
fertilized egg itself (Pagon et al., 2016). 
Driver gene: A gene that contains driver gene mutations (Mut-Driver gene) 
expressed aberrantly in a fashion that confers a selective growth advantage (Epi-Driver 
gene). 
Epigenetic: Denoting processes by which heritable modifications in gene function 
occur without a change in the sequence of the DNA (Spraycar, 1995). 
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Etiopathogenesis: A portmanteau of etiopathology and genesis; the cause and 
development of a disease or abnormal condition (Merriam-Webster, n.d.). 
Family cancer history (FCH): Familial pancreatic cancer referred to in this study 
simply as family cancer history (FCH), cancer predisposition genes (CPG), or shared 
genes—elaborating on the known genetic syndromes (Rustgi, 2014), and germline 
mutations such as BRCA2 (Grant et al., 2015). 
Gene-environment interaction: In genetic epidemiology, genetic factors that 
confer susceptibility or resistance to pancreatic cancer in a particular environment 
(Khoury, Davis, Gwinn, Lindegren, & Yoon, 2005; Willett, 2002). 
Genetic heterogeneity: The character of a phenotype produced by diverse 
mechanisms that can be distinguished by special methods such as linkage analysis but are 
ordinarily indistinguishable. 
Genetic polymorphism: The occurrence in the same population of two or more 
alleles at one locus, each with appreciable frequency (Cavalli-Sforza & Bodmer, 1971). 
Genome theory: A model used to guide the understanding of timing occurrence of 
genetic events in pancreatic carcinogenesis and progression (Makohon-Moore et al., 
2013). 
Germline genome: An individual’s genome as inherited from his or her parents 
(Vogelstein et al., 2013). 
Germ theory of disease: In the context of the 21st century, a framework in which 
the number of variants resulting in disease equals one (Whitcomb, 2014). 
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Inherited cancer predisposition: A means to identify genes that may have 
significant normal roles in the control of growth and differentiation, and which when 
faulty can predispose to malignancy (Ponder, 1991). 
KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog): One of a class of 
genes known as oncogenes, which when mutated have the potential to cause normal cells 
to become cancerous (Kranenburg, 2005). 
Latency period: The delay between a cause and its effect, or the time between 
causal factors and diagnosis (Spraycar, 1995). 
Metatheory: The integration of various theories (Anchin, 2008; Ritzer, 1988). 
Multilevel biologic and social integrative construct (MBASIC): A model that 
guides transdisciplinary collaborations to maximize the value of multilevel studies for 
clinical and public health activities, and to integrate macro environment and individual 
factors with biology (Lynch & Rebbeck, 2013). 
National familial pancreas tumor registry (NFPTR): A research registry 
established at Johns Hopkins University in 1994 (Shi, Hruban, & Klein, 2009). 
PALB2 (Partner and Localizer of BRCA2): A pancreatic cancer susceptibility 
gene; PALB2 mutations occur in patients with familial pancreatic cancer (Jones et al., 
2009).  
Pancreatic cancer (PC): The predominant histologic type of cancer in sporadic 
and familial cancer of the pancreas estimated to become the second leading cause of 
cancer death in the United States by 2020 (Rahib et al., 2014). 
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Pancreatic ductal adenocarcinoma (PDAC): Referred in this study as pancreatic 
cancer (PC), representing the fourth leading cause of cancer mortality worldwide, with an 
incidence of approximately 217,000 new cases each year nearly matched by 213,000 
deaths (Parkin, Bray, & Devesa, 2001). 
Pathometry: The determination of the proportionate number of individuals 
affected with a certain disease at a given time, and of the conditions leading to an 
increase or decrease in number (Stedman, 2012). 
Pathopoiesis: The tendency of an individual to become ill; the mode of 
production of disease. 
Postmodernism: A reaction to the assumed certainty of scientific or objective 
efforts to explain reality (Stringer, 2014). 
Subclonal mutation: A mutation that exists in only a subset of the neoplastic cells 
within a tumor (Vogelstein et al., 2013). 
Susceptibility gene: A gene mutation that increases an individual’s susceptibility 
or predisposition to a particular disease or disorder.  
Tobacco use: A modifiable risk factor associated consistently with a twofold 
increased PC risk (Jansen et al., 2015).  
Traditional evolutionary theory: A model explaining evolutionary processes that 
drive cancer progression; the model helps in understanding tumor growth dynamics to 
narrow the search for specific mutations that drive different aspects of the disease 
(Rodriguez-Brenes, Komarova, & Wodarz, 2013). 
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Tumor suppressor gene: A gene that when inactivated by mutation increases the 
selective growth advantage of the cell in which it resides (Vogelstein et al., 2013). 
Assumptions, Limitations, Scope, and Delimitations 
Assumptions 
By the year 2020, PC is estimated to become the second leading cause of cancer 
death in the United States (Chari et al., 2015). Tobacco use may be not only a cancer-
causing agent but also a lifestyle-related factor associated with the etiopathogenesis of the 
disease. Familial pancreatic cancer is thought to be genetically heterogeneous (Zhen et 
al., 2015), and other inherited mutations are referred in this dissertation as FCH or CPG. 
All calculations were conducted under the assumption of the association of smoking, 
gender, and age to individuals with FCH, or the synergism of these factors in the 
initiation of pancreatic cancer. Yes/no P16(CDKN2A), PRSS1, BRCA1, STK11/LKB 
genes among participants with FCH, or smoking history as the binary outcome, was 
explored in correlation with the disease prevalence. The probability of developing 
pancreatic cancer is virtually impossible to tell. Therefore, it is important to examine the 
pathopoiesis mechanism of smoking as a lifestyle-related factor or modifiable risk factor 
in correlation with gender, age, and CPG in the development and progression of 
pancreatic cancer. 
Scope and Delimitations 
The occurrence of PC/CTS-GA under the defined combined role of risk factors in 
this dissertation was sparse or rarely discussed in previous research. Hassan et al. (2007) 
asserted the need for further assessment of the synergistic interaction between smoking 
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and diabetes, and positive family history of pancreatic cancer in other large-scale 
epidemiological studies of different populations, in men and women separately. Gender 
and age were included in the statistical analysis to establish connections at a single point 
in time, in addition to smoking lifetime history or its combined role in the prevalence of 
PC and CTSG-A, statistical adjustment through age post-stratification (<51, 52-69, 70>) 
to weight for probable selection bias. Reported age of onset for familial pancreatic cancer 
(FPC) collated from previous investigations was 52-69 years (Norris et al., 2015). In the 
current study, gender, race/ethnicity, and age were considered for statistical analysis to 
assess differences in induction and promotion of PC.  
The sampling frame of this study included randomly selected data from the 2014 
BRFSS. To achieve generalization, G*Power was used to establish sample size. If the 
suggested sample size failed the ordinal logistic regression assumptions, the remaining 
sample after data cleaning was used. Producing well-grounded evidence would contribute 
to the mission of the source of the secondary data. Emphasizing the impact of modifiable 
or lifestyle risk factors such as smoking in the induction and promotion of PC may 
promote not only positive social change but also future studies in establishing a national 
or international consortium for PC to develop a risk model for early detection of the 
disease (Hassan et al., 2007). 
Limitations 
Given the time involved and other challenges in establishing institutional 
collaboration between Walden University and the Johns Hopkins University National 
Familial Pancreas Tumor Registry (NFPTR), the 2014 BRFSS data sets were used in this 
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study. Limitations of secondary data include missing data and reusing existing data sets 
from previous studies. Although it was important to be aware of ethical issues and 
weaknesses of using secondary data, following the minimum standards of preparing the 
2014 BRFSS Module for analysis was critical to the quality of this study. 
Significance of the Study 
By the year 2030, it is projected that PC will be the second leading cause of 
cancer death after lung cancer among the major types of cancer (Rahib et al. 2014). The 
outcome of this study would provide valuable insights into the etiopathogenesis of PC 
and CTS-GA, as well as the possible recognition of the probable unique pattern of PC 
malignancy among defined age groups, between men and women, in correlation to the 
modification effect of smoking to CPG, or its combined impact. Additional 
understanding of the pathopoiesis dynamics of smoking status, gender, and age in 
individuals with CPG in the induction and promotion of PC could help promote pre- and 
post behavioral diagnosis change. This study may assist in developing a novel patient 
management approach to accurately assess the disease burden under the lens of public 
health and modern epidemiology.  
Variability of previous exposures and cumulative effects of smoking, and 
prevalence patterns among defined age groups between men and women in association 
with individuals with CPG versus nonsmokers with CPG could explain the difference in 
latency periods and degrees of pancreatic cancer progression. Exploring the combined 
arbitrary role of smoking and CPG in the progression of PC may confirm the importance 
of addressing the need for fostering behavioral change by adopting healthy habits among 
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high-risk individuals. Moreover, this study could provide further insights into behavior, 
prevention, and mechanisms associated with PC risk. Although the procarcinogenic 
effects of tobacco use on the pancreas are inadequately studied (Pandol et al., 2012), 
closing the gap in knowledge continuity in the understanding of PC epidemiology 
regarding the association between smoking and shared genes that could impose comorbid 
conditions was critical to the advancement of efficient clinical practice. The focus of 
most research in PC epidemiology is on the improved understanding of risk factors in 
association with clinical treatment to alter the expression or final stage of the disease. 
Following the blueprint of public health intervention, this study focused on understanding 
the interaction between biologic, individual, and microenvironmental factors in the 
induction and promotion of PC. The outcome of this study may justify the importance of 
behavioral change. 
Positive Social Change Emerging from the Study 
The commonality of modernism and 21st century thinking (postmodernism) is the 
goal of living the highest quality of life. The greatest challenge of this study was to 
improve the outcome of those diagnosed with PC and CTSG-A known to have increased 
risk of extrapancreatic malignancies. Patients diagnosed with PC have a poor prognosis 
of 28% 1-year survival rate, and 4-7% 5-year survival rate (American Cancer Society, 
2015). The only way to stop the fear after being diagnosed with PC is by managing 
emotional issues and social concerns. People may sometimes struggle with changes in 
their social roles or situation, but high-risk individuals have a choice to make lifestyle 
changes. The 21st century thinking underscores the noteworthiness of making healthy 
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lifestyle changes that affect not only the risk of developing the disease but also the ability 
to function independently in later life. The 21st century approach to advancing the vision 
for prevention requires innovative steps on integration and a comprehensive way of 
promoting public health. Part of creative actions is accepting the significance of social 
change in the sphere of enhanced quality of life. Focusing on the impact of cigarette 
smoking as a modifiable risk factor that promotes PC and CTSG-A rather than initiates it 
may amplify the importance of behavioral change promoted through health care policy 
changes. According to a report on recommendations of the Task Force on Community 
Preventive Services (2000), assessment of current tobacco-use prevention and cessation 
activities is paramount in the development of a comprehensive strategy to reduce 
initiation, increase cessation, and reduce exposure to environmental tobacco smoke. 
Parallel to this recommendation, Bunnell et al. (2012) stated that future work to combat 
interrelated economic and health challenges could build on the Communities Putting 
Prevention to Work (CPPW) approach. Benefits from the strategic selection of priorities, 
robust support for individual community needs, and enhanced accountability to ensure 
fidelity to the design of program plans (Bunnell et al., 2012) may improve the CPPW 
approach in implementing evidence-based tobacco-use interventions. 
Summary 
In this chapter, I addressed smoking as the strongest avoidable risk factor for PC 
and CTSG-A along with other predictors (age, gender) emphasizing the intent of this 
study was not only to explore its likely modification effect among individuals with CPG 
but also to highlight the positive social change through smoking cessation. Moreover, the 
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call for further research on the procarcinogenic effects of smoking (Pandol et al., 2012) 
was acknowledged. Conceding the need to investigate the genetic and environmental 
interactions associated with the increased PC risk (Schenk et al., 2001) affirmed the 
significance of the development of prevention and control strategies and lifestyle changes 
to reduce cancer risk. Exploring predictors’ association with CPG may contribute to the 
understanding of pancreatic carcinogenesis, critical to the advancement of efficient 
clinical practice.  
The outcome of this study may provide valuable information to future researchers 
improving current understanding of genomic instability, one of the leading causes of 
genetic heterogeneity (Burrell et al., 2013). Previous studies indicated that this disease 
has a complex genomic landscape (Campbell et al., 2010). It was therefore critical to 
explore the extent of the current understanding of PC, to recognize the probable effect 
modification of smoking, and to examine the correlation of gender and age to disease 
initiation and progression among individuals with CPG. Chapter 2 provides an in-depth 
review of the literature addressing the cancer genome landscape, patterns, dynamics of 
genomic instability in PC evolution, and the etiopathogenic role of tobacco use. The 
accumulation of mutations in a variety of genes is discussed, antecedent to the 
procarcinogenic effects of smoking, making the disease a highly malignant tumor with 
few viable therapeutic options (Makohon-Moore et al., 2013).  
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Chapter 2: Literature Review 
The early symptoms of pancreatic cancer (PC) often mimic other benign 
conditions, and its biological complexity adds challenge to early detection, resulting in a 
highly malignant tumor with few viable treatment options. The evolution of PC 
progression involves its genetics from initiation to the tumor’s ability to adapt and grow 
even with intense therapy. The primary reasons for its poor clinical resistance are early 
metastasis, chemoresistance, and late clinical outcomes. Asymptomatic in the early 
stages, PC is a highly lethal cancer difficult to detect with a median survival of less than 
6 months, and a 5-year survival rate of less than 5% (Klein, 2012). According to Yachida 
et al. (2010), it takes at least 15 years from the time of the initiating mutation to 
metastasis, making the tumor unresectable and aggressive in a metastatic state by the time 
PC is diagnosed. Vital to the development of therapies, mapping of the PC genome that 
target many genetic abnormalities will aid in the understanding of pancreatic 
carcinogenesis, crucial in improving clinical outcomes.  
The mechanisms through which smoking, gender, age, and cancer predisposition 
genes (CPG) affect PC remain unknown, making it critical to explore the role of these 
three predictors in the disease clustering to develop a more efficient management and 
clinical approach. With an exhaustive understanding of the patterns of somatic alteration 
in pancreatic carcinogenesis comes the opportunity to understand the influence of these 
factors on metastatic progression (Yachida & Iacobuzio-Donahue, 2013). Working 
toward this goal, the key intent of this dissertation was to highlight the pathopoiesis 
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mechanism of tobacco use and CPG, as well as the etiopathogenic role of gender and age. 
New research directions are warranted to reverse the lethal outcome of this disease.  
In this chapter, I provide a scholarly review of literature related to the current 
state of understanding of PC. I searched for peer-reviewed studies on PC using the 
Thoreau database with a restriction on the year of publication from 2011 to 2016. 
Scholarly literature published before 2011 was considered to establish a historical 
perspective on the progression of pancreatic carcinogenesis research. Bookends On Tap, 
a reference management iPAD app, provided current articles across databases including 
PubMed, PubMed Central, Google Philomath, JSTOR, and arXiv. Using Evernote and 
Microsoft OneDrive, I conducted an automated search weekly to identify current 
literature using the myNCBI feature of PubMed. Blogs, non-peer-reviewed papers, and 
forum posts were omitted to ensure that references were of high quality.  
Background 
In the United States, smoking-related illness costs more than $300 billion each 
year (Warren, Alberg, Kraft, & Cummings, 2014), and since the 1970s tobacco use 
remains a major risk factor of PC. According to Pandol et al. (2012), accumulating 
evidence has indicated that carcinogenic compounds from tobacco use stimulate 
pancreatic cancer progression. Pandol et al. noted the economic burden of PC with an 
expected yearly cost of $4.9 billion and underscored the significance of determining the 
mechanisms underlying the effect of smoking compounds that may provide additional 
insights into the pathogenesis of the disease. The investigation gave valuable insights into 
the etiopathogenesis of pancreatic growth from its induction and promotion.  
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The present understanding and the surge of awareness of PC in the 21st century 
began with the significant progress achieved by the discovery of the human pancreatic 
duct in 1642 by Wirsüng, followed by Blobel’s discovery of signaling mechanisms that 
govern the transport and localization of proteins within pancreatic acinar cells in 1999 
(Ceranowicz, Cieszkowski, Warzecha, Kuśnierz-Cabala, & Dembiński, 2015). At 
present, solid tumors are interpreted as alterations in driver genes (Armitage & Doll, 
1954; Vogelstein et al., 2013) that ordinarily require five to eight hits in classic 
epidemiologic studies. According to Vogelstein et al. (2013), several tumors have only 
one or two driver gene mutations, as shown in Figure 2. Given that cancer genome 
sequencing is a relatively new endeavor, the identification of three oncogene mutations 
and six alterations with both oncogene and tumor suppressor gene mutations in PC will 
give way to the most appropriate management plan (Vogelstein et al., 2013). 
The outcome of cancer genome sequencing already had an impact on the clinical 
care of cancer patients. However, a greater emphasis on probabilistic thinking and 
clinician numeracy are essential in the development of new models for creating an 
efficient medical care system centered on the quality of care, extending and improving 
the quality of life for patients diagnosed with PC and CTSG-A. There is a need to 
integrate epigenetics, proteomics, and metabolomics in the analysis of genomic data, and 
the addition of a sophisticated clinical workforce (Krier & Green, 2013) will contribute to 
the management of incidental findings. Additionally, given the significant environmental 
factors’ role in the etiology of sporadic pancreatic cancer (Raimondi, Maisonneuve, & 
Lowenfels, 2009), it is necessary to develop diagnostic tests that not only aid in the 
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identification of susceptible individuals or monitor disease progression, but also aid in 
prevention or guide PC treatment (Hocevar et al. 2014).  
 
Figure 2. The number and distribution of driver gene mutations in pancreatic cancer 
compared to other tumor types (Vogelstein et al., 2013, p. 29). 
 
Pancreatic Cancer Genetic Landscape and Molecular Biology 
Subject to evolutionary paradigms, PC emerged as a disease of inherited and 
somatic mutations from more than two decades of research (Maitra & Hruban, 2008). 
Sequencing of the germline of individuals with a strong family history of pancreatic 
cancer and those with a genetic predisposition to the disease is critical to raising 
awareness of the promise of extrapancreatic neoplasm screening in identifying early 
curable pancreatic neoplasia (Iacobuzio-Donahue, Velculescu, Wolfgang, & Hruban, 
2012). There are three important points to remember about the germline genetic 
syndromes (GGSs) associated with lifetime PC risk. First, quantifying PC risk of known 
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genes responsible for the aggregation of PC in a family is necessary for the design of 
clinical trials of at-risk patients screening for early curable precancerous lesions (Canto et 
al., 2012; Canto et al., 2013). Second, both high and low-penetrance genes except genes 
associated with familial pancreatitis increase the PC risk and extrapancreatic 
malignancies. Lastly, although screening for extrapancreatic malignancies can save lives, 
it is important to remember that some of these GGSs have implications for therapy. The 
changes in the clinical management of neoplasms with somatic mutations begotten by the 
sequencing of the most common types of pancreatic tumors warrant the search for new 
strategies in the early detection and treatment of pancreatic neoplasia (Wolfgang et al., 
2013). 
Endocrine and exocrine pancreatic tumor genetics and biology can be profoundly 
influenced by the particular type of origin, exhibiting considerable divergence in their 
mutational spectra and clinical behavior (Jiao et al., 2011). With regard to the evidence 
for clonal diversity between primary and metastatic sites, Campbell et al. (2010) found 
the amplification of cancer genes predominantly occurring in early cancer development 
and genetic heterogeneity among metastasis-initiating cells. The data presented in this 
study confirmed the richness of genetic variation in cancer. Like Campbell et al. (2010), 
Waddell et al. (2015) also discussed the genomic instability concerning cancer 
dissemination and metastases. In addition to numerous genes mutation at low prevalence, 
Waddell et al. substantiated the importance of V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS), Tumor protein p53 (TP53), SMAD Family Member 4 
(SMAD4), cyclin-dependent kinase Inhibitor 2A (CDKN2A), and AT-Rich Interaction 
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Domain 1A (ARID1A) gene mutations. Waddell et al. found the role of chromatin 
modification and the broader role for aberrant Wnt signaling pathway (KW-0879) in 
recurrent mutations identified in Lysine Demethylase 6A (KDM6A). Waddell et al. 
provided the most comprehensive description of the genomic events that characterized 
pancreatic cancer and demonstrated the prominent structural variation mechanism of 
genomic damage in this disease.  
Worldwide, 85% of PC cases are adenocarcinomas, and 1 to 10 cases per 100,000 
have the incidence of all types of PC. According to Ryan, Hong, and Bardeesy (2014), 
PC has ranked as the eighth leading cause of death among men, and the ninth leading 
cause of death among women globally for the past 30 years. Like Blackford et al. (2009), 
Ryan et al. found the role of KRAS mutations in the etiopathogenesis of the disease. 
Given the risk factors and established genetic syndromes associated with the condition 
(see Table 1), and despite the unidentified genetic basis of familial aggregation, Ryan et 
al. agreed with Klein et al. (2004) that PC has the estimated 5 to 10% unidentified 
inherited component in familial aggregation. Somatic structural rearrangement of 
chromosomes as part of the mutational landscape of PC could lead to the development of 





Risk Factors and Inherited Syndromes Associated With Pancreatic Cancer 
Variable Approximate risk 
Risk factor  
Smoking (Bosetti et al., 2012) 2-3 
Long-standing diabetes mellitus (Ben et al., 2011) 2 
Nonhereditary and chronic pancreatitis (Duell et al., 2012) 2-6 
Obesity, inactivity, or both (Aune et al., 2011) 2 
Non–O blood group (Klein et al., 2013) 1-2 
Genetic syndrome and associated gene or genes— %  
Hereditary pancreatitis—PRSS1, SPINK1 (Rebours et al., 2008) 50 
Familial atypical multiple mole and melanoma syndrome—p16 
(Vasen et al., 2000) 
10-20 
Hereditary breast and ovarian cancer syndromes—BRCA1, BRCA2, 
PALB2 (Iqbal et al., 2012; Jones et al., 2009) 
1-2 
Peutz–Jeghers syndrome—STK11 [LKB1] (Giardiello et al., 2000) 30-40 
Hereditary nonpolyposis colon cancer (Lynch syndrome)—MLH1, 
MSH2, MSH6 (Kastrinos et al., 2009) 
4 
Ataxia–telangiectasia—ATM (Swift et al., 1991) UNKN 
Li–Fraumeni syndrome—P53 (Ruijs et al., 2010) UNKN 
 
Note. Adapted from “Pancreatic Adenocarcinoma” by D.P. Ryan, T.S. Hong, and N. 
Bardeesy, 2014, New England Journal of Medicine, 371(11), p.1040. Copyright 2014 




To date, surgical resection remains the only potentially curative treatment 
according to Zakharova et al. (2012), albeit only 15%-20% of patients with PC are good 
candidates for the procedure. On the other hand, the focus of health care providers on 
prolonging life, helping patients and their family through difficult transitions after 
diagnosis are equally as important as improving survival through the development of 
optimal treatment algorithm (Wolfgang et al.,2013). The increased use of high-quality 
multi-detector computed tomography (MDCT), neoadjuvant treatment with systemic 
chemotherapy, and the enormous strides in exploring the underlying genetics of 
pancreatic cancer are critical parts of an individualized treatment algorithm 
(Varadhachary et al., 2006; Zakharova et al., 2012). The outcome of this dissertation in 
combination with such an innovative, evidence-based treatment plan could improve 
perioperative care and quality of life. 
The particular application of past and current research on inherited mutations to 
this dissertation supports an earlier study by Tersmette et al. (2001) that demonstrated the 
risk of developing PC among first-degree relatives (FDRs) in the family with the disease. 
In this study, the researchers found that PC kindreds with three or more affected relatives 
show a 57-fold (95% CI = 12.4–175) increased the risk of pancreatic cancer. Tersmette et 
al. (2001) stated that although the gene or genes responsible for familial PC have not yet 
been identified, the findings highlighted the importance of the development new PC 
chemoprevention and screening modalities that will benefit this group of individuals (p. 
733). Following this point of inquiry, Ludwig et al. (2011) delve into the rationale for 
strategies in identifying early detection of precursor lesions or early cancers in high-risk 
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groups that could improve disease-specific outcome. The researchers perused the 
significant yield of screening at-risk relatives of familial pancreatic cancer patients. 
Magnetic resonance cholangiopancreatogram (MRCP) was used to screen 309 
asymptomatic at-risk relatives enrolled in the Familial Pancreatic Tumor Registry (FPTR) 
of Memorial-Sloan Kettering Cancer Center (MSKCC) to validate the results of prior 
studies as to the safety and efficiency of MRCP as an initial screening modality. If 
indicated, endoscopic ultrasound with fine needle aspiration was performed. MRCP 
produced a significant diagnostic yield, particularly in family members >65 years of age.  
Akin to the objective of the study of Ludwig et al. (2011), an earlier investigation 
by Klein et al. (2004) examined the significance of familial PC history (FPCH) as a 
rational basis for cancer risk screening and counseling. In this prospective registry-based 
study, using the National Familial Pancreas Tumor Registry (NFPTR) as a resource of 
familial pancreatic cancer (FPC), Klein et al. contrived the probable denotative increased 
risk of pancreatic cancer in FPC kindreds. The quantification of family members 
diagnosed with the disease supported the hypothesis of increased risk among individuals 
with FCH. The study found an increased PC risk with burgeoning numbers incidence 
among FDRs. Parallel to this rationale, several studies asserted a two to a five-fold excess 
of pancreatic cancer in FDRs of patients with PC, augmented among smoking relatives of 
patients with the disease (Brentnall et al., 1999; Schenk et al., 2001). The prospective, 
registry-based study of Klein et al. (2004) help quantified the risk of pancreatic cancer in 
kindreds in which a family member has received a diagnosis of PC (p.2637). The findings 
added to the body of evidence that the familial aggregation of pancreatic cancer is often 
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not due to chance, and demonstrated that a strong family history of PC significantly 
increases the risk of PC development. 
Complex Darwinian Evolutionary System 
Parallel to the Darwinian natural selection, Peter Nowell’s landmark perspective 
on cancer as an evolutionary process is driven by stepwise, somatic cell mutations with 
sequential, subclonal selection (Nowell, 1976). Considered as a legitimate scientific 
theory, the evolutionary theory of cancer has survived 35 years of empirical observation 
and testing (Greaves & Maley, 2012). Whereas the understanding of the essential 
components of somatic evolution is well established, Greaves and Maley (2012) noted 
the tools from evolutionary biology that may be applied to neoplasms to give light on the 
uncertain disposition on the dynamics of somatic evolution and address the fundamental 
questions in cancer biology. The diverse mutational processes involved in carcinogenesis, 
modern cancer biology, and genomics validated cancer as a complex, Darwinian, 
adaptive system (Merlo et al., 2006; Greaves & Maley, 2012). Using a non-spatial 
population genetics model of sequential, exponential clonal expansion, Bozic et al. 
(2010) formulated an equation to pancreatic cancer resequencing data in estimating driver 
mutation. The empirical evidence established by tumor biology and genetics on the 
considerable divergence in the mutational spectra and clinical behavior of endocrine and 
exocrine PCs emphasized the need to advance genomics technologies (Jiao et al., 2011). 
Furthermore, Jiao et al. (2011) noted that making improvements on genomics 
technologies will heighten the understanding of how genomic instability shapes tumor 
evolution. While genomic instability may be an attractive therapeutic target; such 
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weakness can leave distinct genomic footprints through various routes, affecting tumor 
development and patient outcomes (Burrell et al., 2013).  
The genetic complexity of PC, hampers the progress in the identification of novel 
therapies, making the early diagnosis of the disease as one of the few options for 
improved outcomes (Hidalgo et. al, 2015). Such complexity made the dynamics of clonal 
diversification and selection in the foreground to understand neoplastic progression and 
response to therapy. According to Greaves and Maley (2012), the control, delay or 
prevention of cancer mortality is dependent upon the clinical opportunities to address 
evolutionary adaptability of neoplasms. Applying the evolutionary clock model to the 
number of mutations that have been quantified in tumors representing progressive stages 
of PCs lead to two definite conclusions (Jones et al., 2008; Yachida et al., 2010; 
Vogelstein et al., 2013). First, a full-blown, metastatic cancer takes decades to develop, 
and mutations are already virtually present in a significant number of cells in the primary 
tumors (Vogelstein et al., 2013). Second, the timing of mutations verbalized in this study 
is relevant to our understanding of metastasis (Vogelstein et al., 2013), fortifying the 
desideratum for the development of new screening modalities that will justify preventive 
surgical intervention.  
The new insights into the biology and genetics of PC, recognizing CDKN2A (G1 
cell cycle arrest pathway) and p53 (p53 pathway) argued by Ryan et al. (2014) as the 
commonly mutated oncogenes in this study, in addition to new findings regarding KRAS 
mutations, tumor metabolism, and tumor immunology, may be of value in the 
development of new treatments. In addition to discoveries regarding KRAS mutations, 
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tumor metabolism, and tumor immunology, Ryan et al. (2014) emphasized the 
importance of new insights into the biology and genetics of pancreatic cancer, essential 
elements in the development of new treatments. Given the paucity of documented 
presence of branched evolution and clonal diversity between primary and metastatic sites 
in pancreatic tumor development (Campbell et al., 2010; Yachida et al., 2010), cancer 
genomes can be exploited for elaborating the need for developing more effective 
immunotherapies (Vogelstein et al., 2013).  
The Whole-genome and Whole-exome data analyzed in the 2013 study of 
Lawrence et al. suggest a strong correlation between somatic mutation frequency in 
cancers and gene expression level. Lawrence et al. (2013) focused on two dominant 
factors that explain mutational heterogeneity: the gene expression level where the 
germline mutation rate affected by transcription-coupled repair, and replication time of a 
DNA (deoxyribonucleic acid) region during the cell cycle (Fousteri et al., 2008; 
Pleasance et al., 2010). Based on the analysis of the massive amounts of whole-genome 
sequencing, Lawrence et al. (2013) concluded that the accurate accounting of mutational 
processes is dependent upon the precise identification of new cancer genes. Relevant to 
the discussion of mutational processes, it would be beneficial to note the association of 
the familial clustering of PC with several features of the genetic syndromes. Individuals 
with a strong family history of PC with a first-degree relative with the disease have a 2.3-
fold increased risk of developing the malignancy (Amundadottir et al., 2004). The 
increased risk that could be explained by an autosomal dominant inheritance of a rare 
allele (Klein et al., 2004); Maitra and Hruban (2008) noted that the association of the 
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disease with some germ-line genetic alterations could provide insights into its 
pathogenesis. While the absence of a strong family history of cancer cannot be used to 
rule out a germline mutation, according to Maitra and Hruban (2008) shown in Table 2—
most of the germline mutations except those in the Protease, Serine 1 (PRSS1) gene are 
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Note: Genes associated with an increased risk of pancreatic cancer: 3 FDR, 3 or more 
first-degree relatives with PC; FAMMM, familial atypical multiple mole melanoma 
syndrome; HNPCC, hereditary non-polyposis colorectal cancer syndrome; NS, non-
specific. UNKN = Unknown. 
 
From an Evolutionary Model to the Unified Paradigm of Cancer Causation (UPCC) 
Three important events launched the field of cancer epidemiology during the 18th 
century. First, is Bernardino Ramazzini’s study on cervical cancer in 1713, the research 
of Percival Pott in 1775 that led the way on occupational carcinogenic exposure studies, 
and Thomas Venner on the danger of tobacco use in his Via Recta, published in London 
in 1620 (American Cancer Society, 2014). After two centuries when John Hill wrote a 
book entitled “Cautions Against the Immoderate Use of Snuff” in 1761; Krain (1970), 
along with other studies in the 1970s, Wynder, Mabuchi, Maruchi and Fortner (1973) 
explored the causality of tobacco use in the development of PC. Jones et al. (2008) found 
that PCs have an average of 63 genetic alterations that can explain the major features of 
pancreatic tumorigenesis. The intensive genetic studies described by Jones et al. (2008) 
gave way to the better understanding of the core set of pathways and processes, 
embracing the idea of Owens, Coffey, and Baylin (1982) that tumor heterogeneity is a 
fundamental facet of all solid tumors. While PC has few viable treatment options, Jones 
et al. (2008) suggested that the best hope for therapeutic development may lie in the 
discovery of agents that target the physiologic effects of the altered pathways and 
processes rather than their gene components. Above all, the significance that could not 
have been appreciated in the absence of global analysis is the identification of the precise 
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genetic alterations that may be responsible for tumor pathway dysregulation (Jones et al., 
2008). 
The pathogenic theory of medicine or the germ theory of disease was highly 
controversial when first proposed as a concept that microorganisms are the cause of many 
diseases. After validation in the 19th century, germ theory revolutionized both medical 
thought and the art of surgery, becoming a fundamental part of modern medicine and 
clinical microbiology. The UPCC, a metatheory in this dissertation as a composite of 
germ theory and Darwinian evolutionary system (Greaves & Maley, 2012) along with 
other theories mentioned in the previous chapter will provide clarity on the narrative of 
the initiation of PC. Albeit the acceptance of the somatic mutation theory of 
carcinogenesis (SMT) as the mainstream narrative of how neoplasms develop (Soto & 
Sonnenschein, 2004), SMT included in the UPCC’s cocktail of theories will build on the 
arguments of the core principle of genetic variation and pattern of mutations 
(environmental and genetics) that are sufficient probable causes of the disease. In this 
chapter, UPCC will explain the behavior of PC cell in rationalizing the complex array of 
the possible interaction of smoking and inherited genes.  
Pancreatic cancer is the fourth commonest cause of cancer death in Western 
societies and is projected to be the second leading cause within a decade (Waddell et al., 
2015). As a consequence, this dissertation will address the urgent need to follow through 
in the assessment of EGBIs and fill the gap of prior studies of not considering the 
reasonable modification of environmental exposures (smoking) to the genomic landscape 
of the disease. While using the Darwinian methods links human sociocultural progress to 
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genetic evolution (Richerson & Boyd, 2000); Lynch and Rebbeck (2013) used a “Multi-
level Biologic and Social Integrative Construct” (MBASIC) to integrate macro 
environment and individual factors with biology. Considering the limitation and 
information generated by single-level studies have reached a saturation point (Lynch & 
Rebbeck, 2013), this dissertation acknowledges the significance of individual level 
(behaviors, carcinogenic exposures); and biologic level (inherited susceptibility variants). 
Germline changes associated with PC (see Appendix) could range from slightly increased 
risk (low penetrance genes) to high lifetime risk (high penetrance genes). Given that PC 
is the antecedent of inherited (germline), and acquired (somatic) mutations in cancer-
causing genes, adding the probable correlation between gender and age, modifying effect 
of smoking to the equation that could trigger or wake up a sleeping germline mutation 
could position the result of this dissertation for improved public health intervention, 
translation and implementation in clinical settings to alter the expression of the disease. 
Smoking: A Modifiable Behavioral Risk Factor 
Tobacco smoking is recognized as a significant environmental factor and the 
strongest avoidable risk factor, and Pandol et al. (2012) highlighted the need for further 
research on its procarcinogenic effects. The gap of this 2012 study was explored by 
Schulte et al. (2014), and the researchers comprehensively discussed the tobacco 
component primarily relevant to pancreatic cancer risk (PCR). Regression models were 
employed in this study generating statistical results broadly consistent with the 
association of both smoking intensity and smoking duration to PCR. The conclusion 
justified the role of smoking pattern in the greater risk of developing the disease. While 
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Pandol et al. (2012) and Schulte et al. (2014) are closely akin in investigating the 
association between cigarette smoking and PC, the outcome of the study of Schulte et al. 
(2014) complements the findings of Blackford et al. (2009) on DNA damage as the 
antecedent of tobacco carcinogens. Whereas the study confirmed an increased mutation 
trends among smokers, in contrast to previous research, the researchers did not observe 
an association between KRAS gene mutations and tobacco use. KRAS is one of the 
molecular switches in signal transduction and one of the genes belonging to the Ras gene 
family. Malignant Phenotype cell transformation is the direct result altered by protein 
products expression generated by point mutations in codons 12, 13, and 61 of KRAS 
(Vogelstein et al., 2013).  
Blackford et al. (2009) demonstrated the best use of methodology and statistical 
approach that helped explore the number of mutations in PC in association with cigarette 
smoking. Given that smokers may develop the disease more frequently at a younger age, 
the researchers found no difference between the mutation of driver genes among smokers 
and non-smokers. The types and patterns of mutations found in PC, provided insight into 
the mechanisms by which cigarette smoking causes the disease (Blackford et al., 2009). 
While the mutations found on PC, have a strong association with cigarette smoking, the 
findings in this study did not produce a characteristic profile. Like Crous-Bou et al. 
(2007), Blackford et al. (2009) noted that previous researchers overlooked the distinction 
between the passenger and driver mutations that explains the often unconvincing 
associations between smoking and driver mutations. Recognizing this gap, and while 
there are continued studies on different aspects of the PC genomic landscape, the intent 
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of this dissertation is to provide a descriptive analysis of the prevalence pattern of PC and 
CTSG-A known to have increased risk of extrapancreatic malignancies versus non-
smokers. 
Connecting the Dots: Smoking and Genetic Aspects of Pancreatic Cancer 
The lack of effective screening tests makes the detection and treatment of PC an 
Augean task, albeit the substantial gains in the last 40 years on the knowledge of its 
epidemiology. The past efforts into understanding the pathosis and epidemiology of PC 
established the basis for scholarly introspection on many current inquiries focused on the 
association of modifiable risk factors and inherited mutations. The goal of the past and 
present studies falls largely within the confines of understanding the insights of genetic 
alterations and specific modifiable risk factors. Much of the recent research concentrates 
in this line of inquiry; therefore, recognizing the modifying effect of smoking to 
individuals with family aggregation justifies the merit of this dissertation and future 
endeavors. 
Parallel to the study of Klein et al. (2004), Wolfgang et al. (2013) found the 
significant role of tobacco use in the etiopathogenesis of PC to higher smoking rate 
among first-degree family relatives (FDRs) of individuals diagnosed with the disease. 
The findings in these studies suggest that smoking cessation may be particularly useful in 
the familial PC kindreds. Kumar et al. (2014) also examined the pathopoiesis mechanism 
of tobacco use in early stage PC using genetically engineered mouse model (LSL-K-
rasG12D). The study found accelerated formation of pancreatic intraepithelial neoplasia 
(PanIN) lesions in response to smoking and the switching of markers from acinar to 
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ductal type, suggestive to enhanced acinar-to-ductal metaplasia (ADM). In this study, the 
experimental epidemiological data provided a novel mechanism of smoking that induced 
ADM in the presence of constitutively active KRAS mutation. The findings of Kumar et 
al. (2014) enhanced the existing body of knowledge on the role of smoking in the 
etiopathogenesis of PC and opened the gap on the need to explore its modification effect 
among individuals with CPG. 
Hart, Kennedy, and Harvey (2008) asserted the need for further epidemiologic 
work in clarifying the association of PC with many exposures using a precise 
measurement of risk factors, and adjustment of potential confounders. Schenk et al. 
(2001) conducted routine questioning of patients on the family history of PC, the age of 
onset of the disease among relatives, and patient’s smoking status. The study assessed the 
higher risk of PC in FDRs, and the effect of smoking on disease onset among younger 
individuals. Schenk et al. (2001) found that while family history of PC, the age of onset 
of the disease among relatives and patient’s smoking status may identify individuals at 
high risk, it is vital to explore the genetic and environmental interactions (GEIs) 
associated with the disease in future research. The only way to move forward in any 
research endeavor is to revisit the outcomes of past and ongoing studies. From this 
overview, it is clear that numerous research on the role of smoking and CPG in the 
etiopathogenesis of PC has contributed to the understanding of the epidemiology of the 
disease. The findings of these studies support the unique probable contribution of this 
dissertation to the existing body of knowledge, generating a snapshot of a possible 
correlation of smoking, gender, and age to the development of PC and CTSG-A, 
44 
 
enhancing the knowledge on the pathopoiesis mechanism of these predictors in disease 
induction and promotion. The plethora of findings of the past and present studies 
highlighted the causal significance of modifiable risk factors and genetics in the pathosis 
of PC. It would be worthy to discuss further in this chapter its epidemiology, and the 
genetic basis of its development and progression. 
Bridging Cancer Epidemiology and Social Evolution 
Modern epidemiology is a direct result of the paradigm shift from a population-
based (upstream) to a downstream (individual) approach. The impact of modern 
epidemiology such as ‘molecular’ and ‘genetic’ epidemiology (Loomis & Wing, 1990; 
Diez-Roux, 1998) requires an explanatory power that largely dependent upon the 
advances in technology and information systems. The development of the new 
epidemiologic shift recognizes not only the significance of sophisticated technologies that 
go beyond the established genome, proteome, and gene expression platforms, but also 
new techniques of study design and data analysis (Pearce, 1996; Verma, Khoury & 
Ioannidis, 2013). Given the remarkable progress in the last decade in advanced 
technology and new methods for biologic measurements, the reductionist approach of 
modern epidemiology often ignored the major causes of disease. Pearce (1996) argue that 
epidemiology must reintegrate itself into public health and must rediscover the 
population perspective. However, while the new paradigm could produce a lifestyle 
approach to social policy, the cumulative outcome of research in cancer epidemiology 
could equate positive implications to population health.  
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The key figures in the new epidemiologic model not only acknowledges the 
development of new techniques of study design and data analysis but also recognize the 
need for a multidisciplinary approach (social, biologic, statistical), and specifying the 
population group as the unit of study (Susser, 1985). While occupational carcinogens can 
be controlled with some difficulty through regulatory measures (Pearce, 1996), it is 
important to acknowledge the fundamental problem of tobacco use is not by its 
consumption but lies in its production. Pearch (1996) focused on some of these 
fundamental changes in epidemiology over the past few decades and considered the 
concepts of causality involved, as well as their ideological and practical consequences. 
While smoking cessation is the probable social implication of this dissertation, it is 
important to stress the epidemiologic value of a study on the apparent correlation 
between gender and age, modification effect of tobacco use among individuals with PC 
and CTSG-A. The outcome of a risk factor epidemiologic study in individual terms could 
uplift precision medicine to meet the challenges in tailoring medical interventions based 
on patient’s biological profile, genetic and epigenetic traits, giving a better understanding 
of EGBIs. 
Embraced by both biomedical and social determinist frameworks, the interlinking 
of the traditional epidemiologic level of intervention (upstream or distal) and the modern 
epidemiologic level of intervention (downstream or proximal) put public health in the 
conundrum of the proximal-distal divide. Signal the importance of the argument of the 
2008 study of Krieger in replacing the terms proximal and distal from the public health 
lexicon, supports the recommendation of Wemrell et al. (2016) on the critical need for 
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open interdisciplinary debates on the contribution of social theory to the epidemiological 
inquiry. While coping with the demand of the 21st-century, global health could still be 
viewed and approached within the mindset of traditional epidemiology, and the purview 
of molecular and cancer epidemiology.  
The discovery of tobacco smoking as a cause of lung cancer in the early 1950s 
gave the field of epidemiology its recognition (Pearce, 1996), shifting the epidemiologic 
paradigm in the object of study in the mid-20th century on the role of multiple causes. 
Establishing the correlation of age, gender a modifiable risk factor (smoking) with PC 
and CTSG-A requires the use of early and current epidemiologic theories, and 
contemporary mainstream epidemiologic concept coalescing to a UPCC. The complex, 
integrative approach of UPCC supports the views of Loomis, and Wing (1990), Pearce 
(1996), and McEwen and Getz (2013) in embracing the new epidemiologic paradigm 
congruent to the advances in cancer genome sequencing. Theorizing the pathopoiesis 
mechanism of smoking, inherited genes, and association of gender and age in the 
etiopathogenesis of PC/CTSG-A warrants exploration of its causal footprints, conjoining 
both biomedical and lifestyle (Krieger, 2011).  
In this dissertation, follow-up and future research are highlighted on the role of 
molecular epidemiology in emphasizing individual susceptibility to PC will assess the 
relative contribution of modifiable risk factors to non-modifiable genetic factors. In this 
premise, the etiopathogenesis of the disease could be explored from the bottom up. 
Bridging cancer epidemiology and social evolution will be dependent upon the 
incorporation of the strength of the social network and social contagion theory. The 
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testable assumption of the social network theory as its strength states that the social 
structure of the network itself be primarily responsible for determining individual 
behavior and attitudes by shaping the flow of resources which determines access to 
opportunities and constraints on behavior (Berkman et al., 2000). Why choose if a single 
theory cannot make a change? Incorporating these ideas in addition to the composite and 
underpinnings of UPCC could springboard a priori argument on the role of social 
networks in the spread of an intervention such as smoking cessation, or amplifying the 
promotion of the significance of early screening to improve mortality and morbidity.  
While the causal nature of peer effects could be associated with tobacco use; the 
social contagion theory of Christakis and Fowler (2013) set an argument on human social 
networks exhibiting a “three degrees of separation.” Such association could support the 
assumption of spreading the interpersonal influence the acknowledgment of the 
significance of early screening, and the promise of a novel therapeutic approach. Like the 
widely discussed classic paper of Travers and Milgram (1969) on ‘six degrees of 
separation,’ the three degrees of separation or the three degrees of separation rule 
(Christakis & Fowler, 2009) agreed on the premise that telegraph phrases are meant to be 
evocative, and not definitive. For example, the role of interpersonal influence in 
spreading novel ideas such as advances in early screening to achieve a greater therapeutic 
outcome. The preponderance of the evidence that points to the added significance of a 
passive-broadcast viral messaging to create social contagion warrants the recognition of 
the approach. Taking into account factors such as the promise of the outcome of a 
research study in the quality of life, social and economic incentives could expand the 
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social network and amplify social support needed by individuals with PC or any deadly 
diseases. According to Kroenke et al. (2013), effective social support interventions need 
to evolve beyond social-emotional interventions and need to account for disease severity 
and treatment status. 
Personal Genomics, Screening, Surveillance, and Management 
Reducing the cancer-specific mortality of PC lies in early diagnosis and treatment 
(Lennon et al., 2014). Ideally, early detection of the disease should be at precancerous 
stage, and according to Lennon et al., (2014) there are six issues needed to be addressed. 
First is the characterization of the curable lesions, distinguishing the advanced from non-
curable. Second, identify the reasonable window of opportunity to detect localized 
treatable lesions. Third, development of a test or screening tools that could determine the 
compendium of curable localized lesions. Fourth, a method to assess and distinguish 
localized lesions that are treatable from localized lesions that have a reasonable chance of 
progression. Fifth, development of novel screening tests or biomarkers with high positive 
predictive value. Lastly, the continued evidence-based research on the significance of 
early screening as well as research on the understanding of PC’s biological processes that 
have potential implications for the understanding of its etiology, prevention, and therapy. 
Driven by the accumulation of somatic mutations, PC epigenetic modifications, and 
changes in the microenvironment warrant new strategy to investigate disruptions of gene 
expression networks that could uncover key regulators and pathways in carcinogenesis 
(Hoskins et al., 2014).  
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The utilization of population-level screening tests utilizing registered tomography 
(CT) despite neither indisputable confirmation nor proficient assertions about the 
adequacy and cost-viability has been promoted to patients through dissemination into 
practice on amid the previous decade (Burger and Kass, 2009). Inquiries regarding 
doctors’ proficient roles and responsibilities within the setting of medical advancement 
shroud this phenomenon, including the appropriate scope of patient autonomy and access 
to unproven screening technology. Burger and Kass (2009) recognize the medical and 
ethical contrasts between screening recommendation for an individual patient and a 
population health premise. Particular cases were examined to investigate how risk 
factors, evidence, and inclinations impact singular patient screening choices. Direction on 
how screening ought to be done is obscured by specialists’ attention on ethics, 
communication, and governmental issues. The proposal of Rychetnik et al. (2013) on 
expanded evidence-based cancer screening policy and practice could yield significant 
implications on cancer screening research. Stadler et al. (2012) analysis of the literature 
found the association of both BReast CAncer gene one (BRCA1) and BRCA2 mutations 
with the incidence of pancreatic cancer and BRCA2 mutation in the increased risk of 
developing PC. Lucas et al. (2014) proposed environmental and genetic factors as causes 
of PC with BRCA2 gene as the genetic factor of particular importance. The risk of 
pancreatic cancer increases in the individual who has a close relative with the disease, 
with approximately 5-10 % believed to show familial clustering (Lynch et al., 2004; 
Cavanagh & Rogers, 2015). According to Naderi and Couch (2002), PC and germline 
BRCA2 mutations have a younger than average age of onset and tend to be of Ashkenazi 
50 
 
Jewish descent. Cavanagh and Rogers (2015) stated that cancer cases among individuals 
with CPG might be due in part to environmental factors or other genetic factors rather 
than possessing a BRCA1/2 gene mutation. Parallel to this argument, this dissertation 
hopes to inquire about the presumable alteration impact of smoking as a biological and 
modifiable hazard in the PC/CTSG-A induction and promotion. 
Epidemiological theory as argued by Krieger (2011) is the practical necessity of 
thinking about and explaining disease distribution. The combined views of Fernandez, La 
Vecchia and Decarli (1996), Lynch et al. (2009), and Maisonneuve and Lowenfels (2010) 
postulates that the key measures to reduce PC are primary prevention in the form of 
tobacco smoking control or smoking cessation. In this context, given the cornucopia of 
knowledge proliferation from germ theory at its inception to the emerging scientific 
theories on cancer dynamics initiated by the classical evolutionary principles of the 
Darwinian theory (Barbara et al., 2014) forms an integrative web of theoretical causations 
that supports the proposed metatheory in this dissertation referred to as UPCC. 
Evolutionary models and theories vary substantially between gene and culture (Claidière 
& André, 2012). Richerson and Boyd (2000) added to this debate the methodological 
approach of the Darwinian theory. Darwinism is a collection of concepts, empirical 
methods and mathematical tools designed to understand the dynamics of genetics and 
cultural evolution (Richerson & Boyd, 2000). Therefore, this dissertation supports the 
rationale of cultural value transmission of smoking cessation that could lower the risk to 
individuals with CPG. Smoking cessation as a cultural item is a clear implication for 
positive social change.  
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The dynamic interplay of gene-culture transmission recognized in UPCC could 
initiate the evolution of culture that embraces the value of evidence-based screening, 
surveillance, management, and personal genomics. Central to human adaptations is the 
use of socially learned information (Richerson, Boyd & Henrich, 2010), from literacy 
program of a health system, emphasizing the significance of 21st-century approach. The 
combined causal association of a variety of levels as recognized by Lynch and Rebbeck 
(2013) that are linked to cancer incidence and mortality justify the supposition of UPCC. 
It is critical to underscore the magnitude of intercalating the mandatory early screening, 
and management of the health system. Moreover, it is also vital to showcase the weight 
of the cumulative evolution of complex adaptations on the invaluableness of genomics to 
gene-culture coevolution. Acknowledging the health system as a macroenvironment 
factor, in addition to social determinants and environmental exposures such as smoking 
will improve intervention, translation, and implementation.  
While the 2013 study of Lynch and Rebbeck presented the MBASIC to integrate 
macroenvironment and individual factors with biology; UPCC as an integrated 
framework acknowledge the significance of embracing personal genomics, evidence-
based surveillance, screening, and management rooted in a culturally transmitted 
macroenvironment. Should we be tampering with the human genome? The ethical, social, 
and clinical implications of personal genomics continue to trigger debate among research 
communities. Such discussions are a much-needed equipoise to the value of personal 
genomics for understanding disease pathogenesis, vital to improving the prognosis of a 
deadly disease like PC (McGuire et al., 2007; Zakharova et al., 2012; Nagpal et al., 
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2014). Parallel to this view, Canto et al. (2013) purport the merit of surveillance, 
screening, and management of high-risk individuals (HRI) with an inherited 
predisposition to PC, establishing a consensus that high-risk individuals warrant 
pancreatic screening. An earlier study of Canto et al. (2012) asserted the need for 
continued research for optimal method of screening people with an inherited increased 
risk for PC. In this study, the researchers conveyed that rather than focusing screening 
efforts to detect invasive cancers, PC screening, and surveillance program should be in 
identifying and selectively treating asymptomatic high-grade precursor neoplasms. 
Debates over these issues, Zakharova et al. (2012) further argue the need for evidence-
based consensus on the optimal preoperative imaging assessment of patients with 
suspected PC and a unified definition of borderline resectable tumors. Given that multi-
detector computed tomography has been widely accepted, it is necessary to embrace a 
realistic approach concerning the patient’s age, health status, quality of life and recovery 
after surgery. The practical approach discussed in this study on screening, surveillance, 
and management, as well as the improvement in the early detection and prevention, is 
dependent upon the progress in the understanding of the genetic alterations in PC and 
associated precursors and development of biomarkers. 
New Public Health Meets a New Initiative on Precision Medicine 
There has been a rapid expansion of knowledge about human DNA structural and 
sequence variation, since the completion of the Human Genome Project (HGP) in 2001 
(Hood & Rowen, 2013). The growth of publicly available data sets and literature mining 
databases inspired by the HGP’s open approach to data sharing gave way to the 
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identification of commonly dysregulated gene expression networks in pancreatic ductal 
adenocarcinoma (PDAC) that could provide insight into the mechanisms of tumor 
progression (Califano et al., 2012). PDAC is the most common sporadic pancreatic 
cancer, driven by the accumulation of epigenetic modifications, somatic mutations and 
changes in the micro-environment (Hoskins et al., 2014). A genome-wide approach was 
used by Hoskins et al. (2014) to profile gene expression changes between normal derived 
pancreatic samples and tumor. The data examined in this study in the context of 
expression gene sub-networks, implicated a novel, central role for hepatocyte nuclear 
factor 1 alpha (HNF1A) and corroborated the benefits of HNF1A down-regulation in the 
proliferation and survival of pancreatic tumor cells. HNF1A is a transcription factor that 
is known to maintain homeostasis of the endocrine pancreas that regulates pancreatic 
differentiation (Luo et al., 2015). Evident in murine Sleeping Beauty transposon-
mediated somatic mutagenesis models of pancreatic cancer, Biankin et al. (2012) 
identified various and diverse somatic aberrations in genes described traditionally as 
embryonic regulators of axon guidance, particularly slit glycoprotein (Slit) and 
Roundabout receptor (Robo) signaling. The study provided further supportive evidence 
for the potential involvement of axon guidance genes in pancreatic carcinogenesis (p. 3). 
The burden of chronic diseases such as PC is often neglected on the public 
agendas. The increasing annual economic burden of PC is beyond genetics and social 
inequalities, making it necessary to embrace the shift in the level of analysis from 
traditional to modern epidemiologic and New Public Health approach. The significance 
of the successful delivery of the New Public Health both at the level of society and 
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individual behavior (Halpin et al., 2010) justifies the intent of this dissertation on the 
need for further exploration of the pathopoiesis mechanism of tobacco use and FCH, the 
etiopathogenic role of gender and age. The unveiling of the “Precision Medicine 
Initiative” during the State of the Union Address of President Barack Obama on January 
20, 2015, springboard the new effort of revolutionizing a new model of patient-powered 
research that could accelerate biomedical discoveries and provide clinicians with new 
tools, knowledge, and therapies. A near-term focus on cancers with a longer term aim to 
generate knowledge applicable to the whole range of health and disease are the two main 
components of this initiative (Collins & Varmus, 2015). In response to this initiative, 
Francis Collins, director of the National Institutes of Health and Harold Varmus, director 
of the National Cancer Institute acknowledge the near-term promise and the long-term 
benefits of precision medicine that not only requires global collaborations with related 
projects, but also motivating and attracting visionary scientists from many disciplines. 
The avidity of renewed debate on enhancing population health and well-being of the 
least-advantaged people will be dependent upon the success of this initiative with the 
assumption that precision medicine will contribute to the advancement of the health of 
the public and clinical practice. While Bayer and Galea (2015) question the full potential 
of precision medicine, Collins and Varmus (2015) highlighted what it could offer to the 
continued advancement of genomics and the new era of evidence-based disease-specific 
medical care without compromising patient privacy.  
The downstream level of intervention of modern epidemiology through the 
provision of clinical preventive services such as screening and surveillance in concert 
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with public health programs could help explain the complex pattern of pancreatic cancer 
death (McLean, Williams & Lamont, 2013). The complementary role of outcomes 
research and epidemiology (Roger, 2011) can give way to improve the quality of care, as 
well as provide powerful and unique insights on efficient therapeutic approach. The 
practice of developing targeted interventions or medical treatments based on a person’s 
environment, genetics and lifestyle are under the national microscope following the 
Precision Medicine Initiative (McGill, 2015). Precision medicine could readily reduce the 
incidence of PC by directing the focus on predictive testing on high-risk individuals 
before the likely onset of the disease. In the public health sphere, the advances in the 
genomic technology could identify those who unknowingly harbor a mutation in their 
genome, allowing for actionable interventions and a greater focus on disease prevention. 
Summary 
Strategies designed to improve the quality of life and survival rate of patients 
diagnosed with PC needs the continued progress in the identification of novel therapies 
(Hidalgo et. al, 2015). The genetic complexity of this lethal disease warrants the 
understanding of the Whole-exome and Whole-genome sequencing that will further 
advance the understanding of the etiopathogenic role of gender and age, in addition to 
pathopoiesis mechanism of smoking to PC/CTS-GA. Moreover, the dynamics of clonal 
diversification and selection are critical to understanding neoplastic progression and 
response to therapy (Greaves & Maley, 2012). Understanding and preventing therapeutic 
resistance lies in the continued research addressing the many fundamental questions in 
pancreatic cancer biology from the order of progression and mutation processes. The low 
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survival rates associated with this disease makes it critical to focus on improved 
outcomes and development of screening modalities to identify PC while the tumor is 
localized and amenable to surgical resection (Poruk et al., 2013). While Poruk et al. 
(2013) found that the incidence and population death rate from PC is high enough to 
consider population-level screening, the possible barrier to initiating screening strategy is 
the affordability and availability of a screening test with sensitivity and specificity of 
90% that could identify PC patients at a resectable stage. 
Recognized by the “Precision Medicine Initiative,” personalizing treatment 
according to the presence of molecular targets could improve outcomes for patients with 
diseases with poor prognosis such as PC because of its genetic landscape (Chantrill et al., 
2105). The different theories discussed in this chapter that embody the UPCC help 
explain GEIs justifying the gap being explored in this dissertation. Smoking cessation 
and acknowledgment of the value of personalized screening are cultural items that could 
induce positive socio-cultural transformation. Both in the context of traditional and 
modern epidemiology, equitable distribution of health-enhancing technologies, 
information, and treatments will help facilitate more rapid uptake and use of new health 
information among groups with lower SES, eventually reducing cancer mortality and 
achieving health equity (Rubin et al., 2014). Further research on the association of 
genetics and environmental interactions are critically important (Schenk et al., 2001). 
Likewise, Greaves and Maley (2012) asserted the promise of exciting clinical 
opportunities by focusing directly on the evolutionary adaptability of neoplasms and 
designing interventions to slow and direct, or control PC progression. The delivery of the 
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New Public Health both at the level of society and individual behavior (Halpin et al., 
2010) justifies the importance of lifestyle change to reduce cancer risk, as well as its 
significance in prevention, and control of PC progression. Under the lens of Public 
Health and modern epidemiology—the study design, sampling, and statistical approach 
will be discussed in the following chapter. 
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Chapter 3: Research Method 
In the previous chapter, current theory-driven literature was reviewed addressing 
the specific components of pancreatic cancer epidemiology. In the review of the 
literature, I also examined the different risk factors, the significance of screening and 
surveillance, and the importance of genetic sequencing in defining the genetic blueprint 
of pancreatic cancer. Given the new opportunities created by recent genetic discoveries to 
improve the understanding of the molecular summation of pancreatic neoplasms, the 
outcome of this study could provide a meaningful addition to the existing body of 
knowledge on early detection and personalized treatment. To the best of my knowledge, 
the etiologic risk factors within hierarchical levels, bridging the gap between individual, 
macroenvironmental, and biologic levels, have not been examined under the lens of 
modern epidemiology and public health. The gap on the modification effect of smoking, 
age, and gender of individuals with CPG justified the intent of this study. A theory-driven 
approach, as argued by Chen and Rossi (1983), will compensate for shortcomings of 
research designs that do not meet the high standards of a randomized controlled 
experimental model.  
According to Lynch and Rebbeck (2013), most multilevel studies lack a focus on 
the relationship between macroenvironment and individual-level factors, and the 
traditional research on macroenvironment or individual-level factors remains broadly 
defined without accounting for the PC genomic landscape. Lynch and Rebbeck 
highlighted the need for full integration of biologic level elements with 
macroenvironment and individual-level factors. Although smoking is strongly associated 
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with PC, most smokers will not be diagnosed with the disease. On the other hand, 
inherited mutations have a lower to high lifetime risk; some carriers may never be 
diagnosed, even at an advanced age. Considering that risk factors assessed in isolation 
and identified by a standard approach may not produce an in-depth evaluation of the 
complex multifactorial causes of PC, I focused on exploring the etiopathogenesis of the 
disease based on EGBIs at an individual level (smoking) and biologic level (inherited 
susceptibility variants). This approach supported the cumulative effects innards and 
across levels, or within at least two ways (see Table 3). The study design, sample, and 




Hierarchical Level Definitions 
Level Sublevel 
 
Factors at this level can serve as: 
Macroenvironment • Health policy 
(national, state, local 
• Community, 
neighborhood 
• Social and built 
environment 
• Practice setting and 
care providers 
• Family and social 
support 
• Exposures that affect individual risk 
factors 
• Exposures that affect biologic 
processes 
• Contextual variables (Rebbeck et al., 
2010) 
 






• Exposures leading to disease 
• Intermediate between the 
macroenvironment and disease 
 
Biologic • Tissue 
• Cell 
• Somatic genome 
• Inherited genome 
• Processes leading to disease 
• Intermediates and biomarkers 
reflecting the relationship between 
macroenvironmental and individual 
factors 
 
Note. From “Context-dependent effects of genome-wide association study genotypes and 
macroenvironment on time to biochemical (prostate-specific antigen) failure after 





Study Design and Approach 
The causality of tobacco-related mutagenic risk factors and the correlation 
between gender and age and CPG will not only raise awareness of the significance of 
cancer risk screening and counseling but will also increase the understanding of 
environmental, genetic, and biodemographic interaction (EGBI) contributing to the 
development and progression of PC. The results of this study may be used to promote 
lifestyle change in reducing cancer risk. Improving the perceived corollary of individuals 
with inherited genes and quality of life during the expression or final stage of the disease 
is dependent on the favorable adjustment of behavioral risk factors. The intent of this 
study was to explore the association between smoking, gender, and age in individuals 
with CPG. I used a cross-sectional design to determine the prevalence of pancreatic 
cancer and CTSG-A among smokers to answering the research questions: 
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic 
cancer and cancer types with shared gene association (CTSG-A)? 
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.  
H1: Smoking can increase the risk of PC and CTSG-A. 
RQ2: Is there a relationship between the combined role of age and gender in the 
etiopathogenesis of PC and CTSG-A? 
H02: Age and gender have no correlation with prevalence of PC and CTSG-A. 
H2: Age and gender are correlated with the prevalence of PC and CTSG-A. 
The overall risk of nonsmokers remains elevated in former smokers for up to 10 
years or more, although smoking cessation lowers this risk of PC by up to 50% (Iodice et 
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al., 2008; Macleod & Chowdhury, 2006). The potential association of smoking, gender, 
and age as predictors of the outcome variable (PC/CTSG-A) were explored using a cross-
sectional design. The sample size was determined using G*Power (Version 3.1.9.2). 
Given that estimating joint and marginal probabilities was not possible, investigating 
independence of D (PC) and E (Exposure: Smokers in association with PC/CTSG-A) 
nonsmokers with PC and CTSG-A was still possible. Secondary data were recoded and 
randomized using IBM Statistical Package for the Social Sciences (SPSS, Version 23, 64-
bit edition). Although logistic regression makes no assumptions about the distributions of 
the predictor variables (smoking, gender, age), ordinal modeling was the fundamental 
property of the design of this study to test whether smoking level and age are effect 
modifiers to inherited genes or combined causative predictors in the induction and 
promotion of PC and CTSG-A. Regression procedures were used to examine the role of 
smoking in driving the initiation and progression of the disease in individuals with CPG 
(see Schaal, Padmanabhan & Chellappan, 2015). The odds of correlation or its combined 
interaction were examined using ordinal regression analysis. 
According to Knol and VanderWeele (2012), the gap on presenting the analysis of 
effect modification and interaction showed that only 11% of cohort studies and case-
control studies presented individual effects of both exposures and the joint effect of both 
exposure; therefore, it was necessary to assess overall interaction measures. The intent of 
this dissertation was to explore whether smoking (Q) contributed to the increased risk 
among individuals with FCH or CPG (E) on PC (D), where Q, D, and E were 
categorical/ordinal. Given the importance of presenting sufficient information and 
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drawing a statistically significant conclusion, I adopted the recommendations of Knol and 
VanderWeele and included OR and RR. Given that quantitative interaction is sometimes 
referred to as synergism or antagonism, interaction or its combined association was 
explored, which may be of public health interest considering that the effect of CPG as the 
primary exposure (see Figure 3) may vary across the subgroup (smokers, gender, age) 
and could give light to the significance of surveillance and early screening and the 
importance of behavioral change. 
The dependent variable under Level 1 or Category 1 in this dissertation comprised 
cancer types with P16(CDKN2A) and PRSS1 mutations. Known as cyclin-dependent 
kinase inhibitor 2A (CDKN2A gene), p16 gene mutations occur in PC with 10-20% 
approximate risk and 20-34 times greater than that reported in any other tumor type (see 
Tables 1 and 2). Numerous additional studies have indicated a high frequency of p16 
deletion in melanoma, esophageal, lung, pancreas, mesothelioma, bladder, head, and 
neck, breast, acute lymphocytic leukemia, brain, osteosarcoma, ovarian, and renal cell 
lines (Rocco & Sidransky, 2001). The mutations in the serine protease 1 gene or PRSS1 
(Yi et al., 2016) were found to be a major factor of PC according to Zeng et al. (2011), 
with 50% approximate risk and 25%-40% risk by age 70 according to Lowenfels et al. 
(1997). The cancer types that were included as part of this category were pancreatic, 
melanoma, esophageal, leukemia, lung, bladder, renal, brain, osteosarcoma (bone), and 




Figure 3. Q = Smoking, X = Genetic syndrome and associated gene(s), CPG (E), PC (D). 
 
Level two or category two includes cancer types with BRCA1, STK11, and LKB1 
mutations. While p16 is related to breast cancer, BRCA1 is two times to have a relative 
risk of PC, with higher risk by age 70. The human LKB gene (official HUGO symbol, 
STK11) encodes a serine/threonine protein kinase that is defective in patients with Peutz-
Jeghers syndrome (PJS). Mutations occur particularly in lung and colorectal cancer 
(Launonen, 2005). The cancer types that are considered to be part of this category are 
breast, ovarian, and prostate cancer. 
Level three or category three are composed of cancer types with bMLH1, and 
bMSH2 mutations. While the risk by age 70 is <5%, hereditary cancer syndromes that 
infer high cancer risks, require intensive cancer surveillance (Pearlman et al., 2017). It 
was suggested by Pearlman et al. that given the high frequency and broad spectrum of 
mutations, genetic counseling and testing are highly recommended. The cancer types in 
this category are endometrial, colorectal, and stomach cancer. 
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Setting and Sample 
The secondary data in this study was from the 2014 Behavioral Risk Factor 
Surveillance System (BRFSS). Following the standards suggested for secondary analysis, 
descriptive and ordinal logistic regression will be performed (see Figure 4). 
 
Figure 4. Epidemiologic data processing tree. (Based on the 2014 BRFSS and 
hypothetical conceptual cohort). 
 
Description of the Study Population 
The population for the study was defined as participants of the 2014 BRFSS 
survey. Subject selection criteria were set narrowly, by selecting specifically those who 
smoke and do not smoke with PC/CTSG-A (survivorship module), versus non-smokers 
with PC/CTSG-A. Subjects with PC/CTS-GA are those identified with inherited 
susceptibility variants (Table 1, Table 2). Association between smoking, age, gender, PC, 
and PC/CTSG-A are explored using hypothetical conceptual cohort. A hypothetical 
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conceptual cohort is defined as participants from the 2014 BRFSS survey who qualified 
as high-risk based on the level of smoking. 
Sampling: Power Analysis 
In this dissertation, like any cancer research or any other studies, the calculation 
of the sample size is critical, as well as the equal chance of every individual surveyed in 
the 2014 BRFSS in a target population to be included in the sample. It is important to 
remember that while random sampling is the gold standard of a sampling strategy, 
random sampling does not describe the sample or its size as much as it describes how the 
sample is chosen (Kadam & Bhalerao, 2010). Integral in generating ethically and 
scientifically sound results is to calculate the optimum number of required sample. Given 
the calculation of adequate sample size is pivotal, it is essential to remember that both the 
practicality of testing methodology and the statistical significance of the sample size are 
similarly critical. According to Kadam & Bhalerao (2010), the sample size for any study 
is dependent upon the power of the study, expected sample size, an acceptable level of 
significance, standard deviation and underlying event rate in the population. The “level of 
significance” in this dissertation is a significant p-value of <0.05. A power analysis 
(computed a priori: required sample size – given α, power, and effect size) was 
performed to estimate the effect size using G*Power (Version 3.1.9.2). While in large 
studies, the power is occasionally set at 90% to reduce the 10% possibility of a “false 
negative” result, I will accept a power of 80% with a total sample size of 116 (see Figure 
5). However, the sample size of 116 after power analysis (PA) failed the ordinal logistic 
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regression assumptions; therefore, the remaining sample after data cleaning was utilized 
in this dissertation. 
 
 
Figure 5. Power analysis. 
 
Instrumentation and Materials 
Conceding the fact that the sample and source of the secondary data already 
discussed and defined in this chapter, I would direct the focus to the instrumentation and 
materials required to conduct this dissertation. A description of the processes, dataset, 
and data collection tools is discussed. 
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Eligibility Criteria, Data Set, and Data Collection Tools 
Subjects were selected at random and re-coded after I received IRB approval 
(approval number 12-19-16-0390363). Variables in the data sets are identified under the 
core section (tobacco, gender, age), “cancer survivorship” module of 2014 BRFSS 
survey. Relevant data was kept using data storage device (USB flash drive), a backup 
copy was uploaded to Microsoft OneDrive (Version 8.17.7).  
Assessment of the Reliability and Validity of the Data 
The key assumptions of this dissertation are strengthened by the reputation of the 
Behavioral Risk Factor Surveillance System (BRFSS) as the nation’s premier system of 
collecting data on health-related behaviors, preventive services use and chronic health 
conditions. While the causes of most PC remain unclear with a 5-10% run in families, the 
reliability and validity of BRFSS data will help justify the significance of expanded 
BRFSS, highlighting the need for adding cancer specific modules. Such modules could 
help connect the association of modifiable risk factors and shared genes in the initiation 
of cancer development. 
Data Collection and Analysis 
Data sets of 2014 BRFSS survey was obtained using a data storage device (USB 
flash drive), and a backup copy was uploaded online using Microsoft OneDrive (Version 
8.17.7). Extracted data will be exported, and re-coded using IBM Statistical Package for 
the Social Sciences (SPSS, Version 23, 64-bit edition). Biologically plausible 
relationships between smoking, gender, and age in the initiation and progression of PC is 
quantified using regression methods. While it is relatively easy to consider an additional 
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in regression models, only variables that are clinically meaningful were included in this 
study. Regression methods were used to assess and adjust for confounding, and determine 
whether there is effect modification, as well as simultaneously evaluate the relationships 
of risk factors (smoking, age, gender). Given that this study involves PC/CTSG-A, and 
more than one independent variables, ordinal logistic regression analysis was performed 
to assess confounding and effect modification. The impact of multiple risk factors 
(smoking, gender, age) is examined as opposed to focusing on a single risk factor. Two 
separate logistic regression analyses (see Table 18A-C) was conducted to assess 
differences in induction and promotion of pancreatic cancer/CTSG-A by gender and three 
age groups (<51, 52-69, 70>). According to Langkamp, Lehman, and Lemeshow (2010), 
the technique of dropping cases with missing data should be discouraged; but in this 
study, the sample size was big enough to drop missing attributes, and stratified sampling 
will optimize generalizability. 
Summary 
The population for this study was defined as participants of the 2014 BRFSS 
survey. The study is a cross-sectional model to examine the association of smoking, age, 
and gender or its combined causality to individuals with PC/ CTSG-A. Secondary data 
was re-coded and randomized through stratification, and regression modeling was 
performed using IBM Statistical Package for the Social Sciences (SPSS, Version 23, 64-
bit edition). Countering the threats to external and internal validity was guided by the 
consideration of the importance of generalizability of the research data, passing the 
assumptions of the statistical analysis used, and stratification to deal with possible 
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confounders. The result of this examination will not only bring to light the 
noteworthiness of cancer risk screening and counseling but additionally will expand the 
understanding of the evolution of PC/ CTSG-A. The expected promise of this study will 
give light to the importance of lifestyle change to reduce cancer risk, promote prevention, 
and control of PC progression. To the best of my knowledge, exploring the etiologic risk 
factors within hierarchical levels, bridging the gap between individual, 
macroenvironmental and biologic level has not been examined under the lens of modern 
epidemiology and public health. The findings of the study could support the importance 
of behavioral risk factor and their roles in reducing the prevalence of PC and CTSG-A, 




Chapter 4: Results 
The purpose of the study was to explore the association between smoking as a 
shared environmental factor in individuals diagnosed with pancreatic cancer (PC) and 
CTSG-A and risk of extrapancreatic malignancies. A cross-sectional design was used to 
assess the burden of the disease and the need for public health intervention, planning, and 
allocation of health resources. Although this study did not include a molecular 
epidemiological analysis or provide information about the cause and effect of smoking 
level and PC and CTSG-A (see Table 4B.2, Figure 7), the outcome could highlight the 
significance of cancer-specific modules either as part of optional modules or expanded 
BRFSS. The positive results of this study could establish a working hypothesis for a 
longitudinal study addressing cause and effect, and could guide future improvements in 
the cancer-specific BRFSS survey module or the development of a supernet 
epidemiology surveillance system (SESS). SESS could spur an initiative to combine the 
Surveillance, Epidemiology, and End Results Program (SEER), BRFSS, and other 
monitoring networks in a single integrated system. Using a cross-sectional design could 
determine the prevalence of PC/CTSG-A and other cancers influenced by a shared 
environmental factor (smoking), essential to answering the research questions: 
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic 
cancer and cancer types with shared gene association (CTSG-A)? 
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.  
H1: Smoking can increase the risk of PC and CTSG-A. 
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RQ2: Is there a relationship between the combined role of age and gender in the 
etiopathogenesis of PC and CTSG-A? 
H02: Age and gender have no correlation with prevalence of PC and CTSG-A. 
H2: Age and gender are correlated with the prevalence of PC and CTSG-A. 
Although a cross-sectional cohort study is an underutilized design (Hudson, Pope, 
& Glynn, 2005), it could be used to assess the association between exposures (smoking 
history/level) and the development of PC and comorbid cancer types. Missing attributes 
were dropped after data cleaning, and stratified randomization was performed to achieve 
optimum representation of the survey population. Table 4A and Figure 6 shows the six 
states (Alaska, Iowa, Mississippi, Missouri, Nebraska, and Wisconsin) that used the 
“cancer survivorship” module of the 2014 Behavioral Risk Factor Surveillance System 
(BRFSS) survey. Instead of the suggested sample size from power analysis noted in 
Chapter 3, to achieve generalizable results I used the remaining sample size of Nebraska 
BRFSS data sets based on the distinct CTSG-A as compared to Alaska, Iowa, 
Mississippi, Missouri, and Wisconsin. To provide a good picture of probable associations 
between the dependent (PC and cancer types with S-GA) and independent variables 
(gender, sex, smoking history/level, age), I estimated the prevalence of the dependent 
variable grouped according to CTSG-A at a single point in time (see Table 4C). I 
conducted ordinal logistic regression after recoding cancer types by prevalence 




Cancer Survivorship BRFSS Module by State FIPS Code 
 
 
Frequency Percent Valid Percent 
Valid Alaska FIPS-2 431 6.0 6.0 
Iowa FIPS-19 1150 16.0 16.0 
Mississippi FIPS-28 608 8.5 8.5 
Missouri FIPS-29 1103 15.4 15.4 
Nebraska FIPS-31 3003 41.9 41.9 
Wisconsin FIPS-55 874 12.2 12.2 
Total 7169 100.0 100.0 
 
 





Case Processing Summary After Data Cleaning 
 
Cases 
Included Excluded Total 


















CA Type Accdg. to SG-A  * 
Respondents Gender 
1691 100.0% 0 0.0% 1691 100.0% 
CA Type Accdg. to SG-A  * 
Four-Level Smoking Status 
1691 100.0% 0 0.0% 1691 100.0% 
CA Type Accdg. to SG-A  * 
Three Age Group 
1691 100.0% 0 0.0% 1691 100.0% 
 
Table 4B.2 
Snapshot of CA Type According to SG-A*Independent Variables 
Respondents Gender N % of Total Sum % of Total N 
Male 692 36.9% 40.9% 
Female 999 63.1% 59.1% 
Total 1691 100.0% 100.0% 
Four-Level Smoking Status    
Current-Smokes Everyday 124 7.0% 7.3% 
Current-Smokes Some Days 36 2.0% 2.1% 
Former Smoker 655 37.8% 38.7% 
Never Smoked 876 53.1% 51.8% 
Total 1691 100.0% 100.0% 
Three Age Group    
<51 126 7.0% 7.5% 
52-69 659 37.8% 39.0% 
70> 906 55.2% 53.6% 






Figure 7. CA type according to SG-A. 
 
Prevalence Proportion 
PC prevalence proportion (PP) and PP of other cancer types were grouped based 
on shared association with PC/ CTSG-A (see Table 2) and computed to obtain the main 
outcome measure. 
Table 4C 
Frequency Table of CA Type According to SG-A 
 
 Frequency Percent Valid Percent 
Valid P16(CDKN2A)/PRSS1 691 40.9 40.9 
BRCA1/STK11/LKB1 769 45.5 45.5 
bMLH1/bMSH2 231 13.7 13.7 




Number of cases in a defined population at one point in time 
 PP = 
Number of persons in a defined population at the same point in time 
PP = P16(CDKN2A)/PRSS1 ÷ 1691 
   = 691/1691 
   = 0.4086 x 100 
   = 40.9% 
PP = BRCA1/STK11/LKB1 ÷ 1691 
   = 769/1691 
   = 0.4547 x 100 
   = 45.5% 
PP = bMLH1/bMSH2 ÷ 1691 
   = 231/1691 
   = 0.1366 x 100 
   = 13.7% 
Analysis 
Defining the gene and environmental factors that lead to the induction and 
promotion of the disease is essential to intervention and management development. 
Snapshot of the frequency of PC and cancer type with CTSG-A was generated in 
correlation to exposure variables using descriptive statistics. Frequency pattern of 
outcome variables allocated by recoded categorical numbers assessed in association with 
a dichotomous, polytomous, and continuous predictors (gender, smoking status, age). 
77 
 
The ordinal dependent variable (cancer type according to the shared gene 
association), and independent variables that are continuous, dichotomous and polytomous 
(age, gender, smoking status) in this study passed the first two ordinal logistic regression 
assumptions of my study design. There are four assumptions needed to be considered: 
1. One dependent variable, measured at the ordinal level. 
2. One or more independent variables that are dichotomous, continuous, 
categorical or ordinal. 
3. There should be no multicollinearity. 
4. The presence of proportional odds. 
Before moving on to test the above assumptions, the PLUM ordinal regression 
procedure was run for the reliability of overall goodness-of-fit measures. Ideally, there 
should be no zero frequency to move on in interpreting and reporting the goodness-of-fit 
measures, or have 80% or more expected cell frequencies. The dataset before power 
analysis (PA) has 4 (5.8%) with zero frequencies, versus 69.4% with zero frequencies 
after power analysis. Therefore, the remaining sample size after data cleaning and re-
coding (before PA) was used in this dissertation. Assumption “3” was confirmed by 
running linear regression procedure. Based on the coefficient table, tolerance values are 
greater than 0.1 (the lowest is .349) with all the variance inflation factors are much less 








1 Respondents Gender .933 1.072 
Three Age Group .967 1.035 
Current-Smokes Everyday .349 2.866 
Former Smoker .361 2.768 
Never Smoked .589 1.697 
a. Dependent Variable: CA Type Accdg. to SG-A 
 
Given that the data set passed assumption “3,” separate binomial logistic 
regression is performed, followed by PLUM, and GENLIN procedure. Assessed by a full 
likelihood ratio test to compare the fit of the proportional odds model to a model with 
varying location parameters, X2(5) = 6.497 with a p-value of .261. The test of parallel 
lines is suggestive to passing the assumption of proportional odds (assumption 2), as 
noted in the difference between the models, and the p-value greater than .05 (.261). 
Table 6 
Test of Parallel Linesa 
Model -2 Log Likelihood Chi-Square df Sig. 
Null Hypothesis 191.698    
General 185.202 6.497 5 .261 
The null hypothesis states that the location parameters (slope coefficients) 
are the same across response categories. 
a. Link function: Logit. 
After running the PLUM-ordinal regression, there are 4 (5.8%) with zero 
frequencies; therefore having 94.2% expected cell frequencies is indicative of the 
reliability of overall goodness-of-fit measures. Both the Pearson and deviance goodness-
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of-fit test was a good fit to the observed data with p-values >.05. The final model 
statistically significantly predicted the dependent variable over and above the intercept-





 Chi-Square df Sig. 
Pearson 38.011 39 .515 
Deviance 41.325 39 .369 
Link function: Logit. 
Table 8 
Model Fitting Information 
Model -2 Log Likelihood Chi-Square df Sig. 
Intercept Only 290.788    
Final 191.698 99.090 5 .000 
Link function: Logit. 
 
While the “Tests of Model Effect” shows that smoking status has no significant 
effect on the prediction of developing PC and CTSG-A; gender is statistically significant 
predictor with p = .000, Wald X2(1) = 75.507. This predictor has a statistically 





Tests of Model Effects 
Source 
Type III 
Wald Chi-Square df Sig. 
Gender 75.507 1 .000 
Smoking Status 2.038 3 .564 
Age 17.538 1 .000 
Dependent Variable: CA Type Accdg. to SG-A 
Model: (Threshold), Gender, Smoking Status, Age 
 
The odds of male respondents developing PC and CTSG-A versus the female 
respondents is .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) = 
75.507, p-value < .0005. An increase in age (expressed in years) was associated with an 
increase in the odds of developing the disease, with an odds ratio of 1.374 (95% CI, 1.184 
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-.005 .1965 -.390 .380 .001 1 .980 .995 .677 1.463 
[CAType_SG_A
=2.00] 
2.303 .2061 1.899 2.70
7 
124.874 1 .000 10.00
8 
6.682 14.991 
Male -.872 .1003 -
1.068 
-.675 75.507 1 .000 .418 .344 .509 
Female 0a . . . . . . 1 . . 
Current-Smokes Everyday -.190 .1867 -.556 .176 1.039 1 .308 .827 .573 1.192 
Current-Smokes Some Days -.326 .3305 -.974 .322 .973 1 .324 .722 .378 1.380 
Former Smoker -.073 .1028 -.275 .128 .507 1 .476 .929 .760 1.137 
Never Smoked 0a . . . . . . 1 . . 
Age .318 .0759 .169 .467 17.538 1 .000 1.374 1.184 1.595 
(Scale) 1b          
Dependent Variable: CA Type Accdg. to SG-A 
Model: (Threshold), Gender, Smoking Status, Age 
a. Set to zero because this parameter is redundant. 





CA Type Accdg. to SG-A * Predicted Response Category Crosstabulation 
 
 











Count 379 312 691 
% within CA 
Type Accdg. to 
SG-A 
54.8% 45.2% 100.0% 
BRCA1/STK
11/LKB1 
Count 264 505 769 
% within CA 
Type Accdg. to 
SG-A 
34.3% 65.7% 100.0% 
bMLH1/bMS
H2 
Count 67 164 231 
% within CA 
Type Accdg. to 
SG-A 
29.0% 71.0% 100.0% 
Total Count 710 981 1691 
% within CA 
Type Accdg. to 
SG-A 
42.0% 58.0% 100.0% 
 
Table 12.1 
Prev1*Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a Male (1) .905 .106 72.231 1 .000 2.472 
Smoking Status   3.343 3 .342  
Current-Smokes Everyday (1) .262 .200 1.730 1 .188 1.300 
Current-Smokes Some Days (2) .341 .349 .952 1 .329 1.406 
Former Smoker (3) .144 .112 1.658 1 .198 1.155 
Age -.349 .082 18.169 1 .000 .705 
Constant .017 .210 .007 1 .935 1.017 




Prev1*Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 99.758 5 .000 
Block 99.758 5 .000 




Step -2 Log likelihood 




1 2187.683a .057 .077 
a. Estimation terminated at iteration number 3 because parameter  
estimates changed by less than .001. 
 
Positive Predictive Value: Prev1 
=100 x (314/248+314)  
= 100 x (314/562), =100 x 0.5587   
= 55.9%. That is, of all cases predicted as having P16(CDKN2A)/PRSS1 genes that 
could directly cause the initiation of PC and other CTSG-A, 55.9% were correctly 
predicted.  
Negative Predictive Value: Prev1 
= 100 x (752/752+377) 
= 100 x (752/1,129) 
= 100 x .6660 
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= 66.6%. That is, of all cases predicted as not having the genes directly responsible for 














Step 1 Prev1 BRCA1/STK11/LKB1/b
MLH1/bMSH2 = No 
752 248 75.2 
P16(CDKN2A)/PRSS1 = 
Yes 
377 314 45.4 
Overall Percentage   63.0 
 
Table 12.5 
Prev2*Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a Male (1) -.553 .105 27.881 1 .000 .575 
Smoking Status   3.562 3 .313  
Current-Smokes Everyday (1) -.250 .198 1.584 1 .208 .779 
Current-Smokes Some Days (2) -.109 .346 .100 1 .752 .896 
Former Smoker (3) -.179 .109 2.702 1 .100 .836 
Age .242 .080 9.121 1 .003 1.274 
Constant -.467 .208 5.063 1 .024 .627 




Prev2*Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 44.897 5 .000 
Block 44.897 5 .000 




Step -2 Log likelihood 




1 2285.464a .026 .035 
a. Estimation terminated at iteration number 3 because  
parameter estimates changed by less than .001. 
 
Positive Predictive Value: Prev2 
= 100 x (395/353+395)  
= 100 x (395/748)  
= 100 X .5280  
= 52.8%. That is, of all cases surveyed to have PC and other CTSG-A, the probability of 
having the BRCA1, STK11, and LKB1 genes have 52.8% positive predictive value. 
Negative Predictive Value: Prev2 
= 100 x (569/569+374)  
= 100 x (569/943) 
= 100 x .6033  
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Step 1 Prev2 P16(CDKN2A)/PRSS1/bM
LH1/bMSH2 = No 
569 353 61.7 
BRCA1/STK11/LKB1 = 
Yes 
374 395 51.4 
Overall Percentage   57.0 
a. The cut value is .500 
 
Table 12.9 
Parameter Estimates and Odd Ratios 
 Prev1 Prev2 
Independent Variable B Sig. Exp(B) B Sig. Exp(B) 
Step 1a Male (1) -.553 .000 .905 .905 .000 2.472 
Smoking Status  .313   .342 
Current-Smokes Everyday (1) -.250 .208 .262 .262 .188 1.300 
Current-Smokes Some Days (2) -.109 .752 .341 .341 .329 1.406 
Former Smoker (3) -.179 .100 .144 .144 .198 1.155 
Age .242 .003 -.349 -.349 .000 .705 
Constant -.467 .024 .017 .017 .935 1.017 






The effect of tobacco use, age, and sex in the etiopathogenesis of PC and CTSG-
A was assessed using cumulative odds ordinal logistic regression with proportional odds. 
While the results of this study supported the null hypotheses that smoking has no 
correlation with the prevalence of PC and CTSG-A as confirmed by the GENLIN 
parameter estimates, both gender and age are statistically significant predictors with <.05 
p-values. The odds of male respondents developing PC and CTSG-A versus the female 
respondents is .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) = 
75.507. The odds ratio of 1.374 (95% CI, 1.184 to 1.595), Wald χ2(1) = 17.538 is 
suggestive to the increased probability of developing the disease as the person reach the 
age between 62 and 69 years of age. The findings of this dissertation support the results 
of Ellison (2017) that the age-specific pattern of PC tends to be at age 60, and 4 in 5 cases 
during 2011 to 2013 were 70 and older. Likewise, separate binomial logistic regression 
analysis shows age was associated with an increased likelihood of developing the disease. 
Analogous to the results of the ordinal logistic regression analysis, the odds of the male 
participants of the 2014 BRFSS survey is 2.472 times greater to develop the disease as 
opposed to female respondents. Further discussion of the results of this study and its 
implication for connecting the association of tobacco use, gender, and age in the initiation 
of PC and CTSG-A will be presented in chapter 5. In addition to a discussion of the 





Chapter 5: Discussion, Conclusions, and Recommendations 
Overview 
Pancreatic cancer has become the third leading cause of cancer-related death, with 
little improvement in mortality and outcomes despite decades of research (Dreyer, 
Chang, Bailey, & Biankin, 2017; Lucas et al. 2016). The need to acknowledge continued 
research is critical to recognize the importance of establishing meaningful, evidence-
based risk prediction models that could be applied in clinical settings to improve the 
accuracy of early identification of premalignant lesions as part of a personalized 
therapeutic approach. Although regular smoking was confirmed as a significant risk 
factor in both sexes by Andersson, Wennersten, Borgquist, and Jirström (2016), the 
association between smoking intensity and duration was not statistically significant in the 
current study. Drawing conclusions about smoking and family history can be complicated 
because both commonly track in the same family and it is difficult to differentiate the 
genetic component from the carcinogen exposure using BRFSS data. The likely impact of 
improved understanding of the etiopathogenic role of gender and age and the 
pathopoiesis mechanism of smoking to PC and CTSG-A prompted the current study. 
A cross-sectional design was used to understand environmental, genetic, and 
biodemographic interactions (EGBIs) and generate hypotheses for future research. The 
purpose of the study was to establish the existence or absence of correlation between 
tobacco use, gender, and age in the etiopathogenesis of PC/CTSG-A, with the intent of 
enhancing the understanding of EGBIs in disease evolution (induction, promotion, and 
expression periods). The following research questions and hypotheses were addressed: 
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RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic 
cancer and cancer types with shared gene association (CTSG-A)? 
H01: Smoking level has no correlation with the prevalence of PC and CTSG-A.   
H1: Smoking can increase the risk of PC and CTSG-A. 
RQ2: Is there a relationship between the combined role of age and gender in the 
etiopathogenesis of PC and CTSG-A?  
H02: Age and gender have no correlation with the prevalence of PC and CTSG-A.  
H2: Age and gender are correlated with the prevalence of PC and CTSG-A. 
Cumulative odds ordinal logistic regression with proportional odds was run, and 
two separate binomial logistic regression analyses were performed to determine the 
effects of age, gender, and smoking level among participants with P16(CDKN2A)/PRSS1 
genes and BRCA1/STK11/LKB1 genes on the likelihood of developing PC and CTSG-A. 
After passing the first two ordinal logistic regression assumptions, the third assumption 
(zero multicollinearity) was confirmed by running the linear regression procedure. Based 
on the coefficient table, the tolerance values were greater than 0.1 (the lowest was .349), 
and all of the variance inflation factors were much less than 10, indicative of zero 
multicollinearity problems. The presence of proportional odds (Assumption 4) was 
assessed by a full likelihood ratio test. Results of the study indicated zero correlation 
between tobacco use and the prevalence of PC and CTSG-A. Both gender and age were 






Germline Genetic Alterations 
Pancreatic cancer (PC) is a disease of inherited (germline) and somatic gene 
mutations (Maitra & Hruban, 2008). In the current study, cancer types of the 2014 
BRFSS cancer survivorship module were grouped based on germline genetic alterations 
that had been recognized and summarized by Maitra and Hruban as having been 
associated with an increased risk of pancreatic cancer. Of the 28 cancer types surveyed in 
the 2014 BRFSS, there were 16 cancer types in the cancer survivorship module known to 
have a shared-gene association (SG-A). These 16 cancer types were grouped based on 
germline mutation genes to establish levels of the dependent variable: 1= 
P16(CDKN2A)/PRSS1, 2 = BRCA1/STK11/LKB1, 3 = bMLH1/bMSH2.  
Multicollinearity and the Increased Likelihood of Developing the Disease 
I created dummy variables to test for the assumption of multicollinearity, and 
created dichotomous cumulative categories of the levels of the dependent variable 
required for the assumption of proportional odds and to run diagnostics that were critical 
in setting up the data set to run an ordinal logistic regression. Dichotomous cumulative 
categories (Prev1, Prev2) of the levels of the dependent variable were created and 
recoded as follows:  
Prev1 = 0 (all other values: BRCA1/STK11/LKB1/bMLH1/bMSH2), 1 
(P16(CDKN2A)/PRSS1);  




The logistic regression model was statistically significant, χ2(5) = 99.758, p < 
.0005. The model explained 7.7% (Nagelkerke R2) of the variance in the outcome 
variable and correctly classified 63.0% of cases. Sensitivity was 45.4%, specificity was 
75.2%, positive predictive value was 55.9%, and negative predictive value was 66.6%. Of 
the three predictor variables, gender and age were statistically significant. Increasing age 
was associated with an increased likelihood of developing the disease. Gender with a p 
value of .000 and age with a p value of .000 added significantly to the model/prediction 
compared to smoking status. Male respondents had 2.472 times greater odds to develop 
the disease as opposed to female respondents. Among participants with 
BRCA1/STK11/LKB1 genes, binomial logistic regression analysis indicated the effects 
of age, gender, and smoking level on the likelihood of developing PC and CTSG-A. The 
logistic regression model was statistically significant, χ2(5) = 44.897, p < .0005. The 
model explained 3.5% (Nagelkerke R2) of the variance in the outcome variable and 
correctly classified 63.0% of cases. Sensitivity was 51.4%, specificity was 61.7%, 
positive predictive value was 52.8%, and negative predictive value was 60.3%. As in 
participants with P16(CDKN2A)/PRSS1 genes, two predictor variables (gender and age) 
among participants with BRCA1/STK11/LKB1 genes were statistically significant. 
Increasing age was associated with an increased likelihood of developing the disease. 
Gender with a p value <.0005 and age with a p value of <.0005 added significantly to the 
model/prediction compared to smoking status. Male respondents had a 57.5% likelihood 
to develop the disease, a statistically significant effect, X2 (1) = 75.507, p-value < .0005 
with   .418 (95% Cl, .344 to .509) times that of female respondents. 
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Proportional Odds Model and Cumulative Odds Ordinal Logistic Model 
Cumulative odds ordinal logistic regression with proportional odds was run to 
determine the effect of tobacco use, age, and gender in the etiopathogenesis of PC/CTSG. 
The assumption of proportional odds was met, as assessed by a full likelihood ratio test 
comparing the fit of the proportional odds model to a model with varying location 
parameter, X2(5) = 6.497 with a p value of .261. The percentage of cells with zero 
frequency was 5.8%; therefore, 94.2% of expected cell frequencies were indicative of the 
reliability of overall goodness-of-fit measures. Both the Pearson and deviance goodness-
of-fit indicated that the model was a good fit to the observed data, X2(39 [Pearson], 39 
[deviance]) = 38.011 [Pearson], 41.325 [deviance], with p values of .515 and .369, 
respectively. The final model significantly predicted the dependent variable over and 
above the intercept-only model, X2(5) = 99.090 with a p value < .001. Although the 
GENLIN parameter estimates showed that smoking status was not significantly 
associated with the outcome, both gender and age were significant predictors. The odds 
ratio of male respondents developing PC and CTSG-A compare to female respondents 
was .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) = 75.507, p 
value < .0005.  
Although the Pearson chi-square results showed Prev1 and Prev2 smoking level 
was statistically significant, cumulative odds ordinal logistic regression showed higher p 
values compared to age and gender. An increase in age (expressed in years) was 
associated with an increase in the odds of developing PC/CTSG-A, with an odds ratio of 
1.374 (95% CI, 1.184 to 1.595), Wald χ2(1) = 17.538, p < .0005. Likewise, the Tests of 
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Model Effect showed that smoking status was not a significant predictor. The 
respondent’s gender was a statistically significant predictor of PC/ CTSG-A with a p 
value <.05, Wald X2(1) = 75.507 indicating statistically significant predictor effect. 
Limitations 
When I started this study, my initial intent was to analyze data from Johns 
Hopkins University National Familial Pancreas Tumor Registry (NFPTR) to address my 
research questions and hypotheses. The data-driven approach and the research question 
approach are the two general approaches for analyzing existing data (Cheng & Phillips, 
2014). According to Cheng and Phillips (2014), these two methods are often used jointly 
and interactively. Using NFPTR secondary data, the research question approach was 
more appropriate, but because of the time and challenges involved in establishing an 
inter-institutional relationship, I decided to move on with analyzing the data from the 
2014 BRFSS. Although my approach remained research question driven, I also 
incorporated a data-driven approach and revised my research questions and hypotheses so 
they could be answered by the available data. However, BRFSS data are not as good and 
thorough as NFPTR data. This may have influenced the validity of my findings. 
In secondary data analysis, there are some limitations that need to be addressed. 
Firstly, missing values that could be caused by skip patterns in long and comprehensive 
surveys like BRFSS are common to reduce interviewer-interviewee burden and burn-out 
by skipping a group of questions that are not relevant for a particular respondent. After 
data cleaning, the variables in this dissertation are the only data that can generate 
statistically significant results and pass the assumptions of the statistical model used in 
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the analysis. Secondly, while using both ‘data-driven’ approach’ and the ‘research 
question-driven’ approach, the limitations of using secondary data resulted in the mixed 
statistical outcome of the association of smoking to cancer evolution. Given that 51.8% 
of the respondents are non-smokers after data cleaning (see Table 4B.2) could explain 
why the results of non-parametric tests (Chi Square tests) are statistically significant (see 
Appendix D and E) compared to the results of the ordinal logistic regression. Lastly, 
given that probability sampling in this dissertation was done using stratified random 
sampling by framing the surveyed cancer types by shared genes association, it is hard to 
draw conclusions about smoking and family history in association to the genetic 
component from the carcinogen exposure. This research endeavor can be initiated using a 
registry data from NFPTR, but not with current BRFSS modules. Therefore, it critical to 
revise existing BRFSS modules, adding cancer specific modules with the history of 
cancer mortality within the family tree genealogy that includes whole-genome 
sequencing (WGS) information. Such revision could compliment future studies using 
registry data, and the development of the epidemiological-genealogical tree, 
complimentary to cancer specific risk history diagnosis scale. 
Implications for Social Change 
Precision medicine may not be synonymous with whole-genome sequencing 
(WGS), but the application of genomic technologies could promote positive social 
change on embracing the promise of WGS in healthy people. The key strategy in using 
WGS is to tailor care to minimize harm to individuals through anticipatory counseling in 
the face of the untargeted nature of the potential findings (Lindor, Thibodeau, & Burke, 
95 
 
2017). This 2017 study further stated that the utility of “next-generation” sequencing had 
been found to establish the diagnosis for hundreds of genetic disorders, to assess 
pharmacogenomic variants, and to identify treatable targets within malignant neoplasms. 
Given that gender and age are the statistically significant predictors in this dissertation 
versus tobacco use, it is paramount to discuss its role, parallel to the overall recognition 
of the WGS’s potential benefits as the ultimate genetic test. Benefits include the 
satisfaction in knowing more about one’s genome, or the with WGS in healthy people 
may include disappointment in how little is interpretable (Dewey et al., 2014; Lindor et 
al., 2015). 
In addition to smoking cessation discussed in previous chapters, the results of this 
dissertation have several implications for social change, such as recognizing cultural 
values in developing effective communication structured from the statistically significant 
etiopathogenic role of gender and age in the development of PC and CTSG-A. This will 
give a clear understanding of what to ask, and what actions to take, allowing the family to 
openly explore treatment alternatives during the terminal phase of the illness (Ballard-
Reisch & Letner, 2003). Primary prevention must be prioritized as an integral part of 
global cancer control. According to Vineis et al., (2014), primary prevention has several 
advantages: the effectiveness could have benefits for people other than those directly 
targeted, avoidance of exposure to carcinogenic agents is likely to prevent other non-
communicable diseases, and the cause could be removed or reduced in the long term 
through regulatory measures against occupational or environmental exposures such as 
environmental tobacco smoke (ETS). However, no regulatory standards nor advanced 
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innovations could change the hearts and minds of the general population unless evidence-
based studies support it. Social change will be dependent upon the continued 
dissemination of current cancer research built on integrative social molecular 
pathological epidemiology (MPE). While remarkable progress has been made in the last 
decade in advanced technology and new methods for biologic measurements; the 
reductionist approach of modern epidemiology often remits the principal causes of 
disease. Pearce (1996) argue that epidemiology must reintegrate itself into public health 
and must rediscover the population perspective. However, while the new paradigm of 
downstream (individual) approach could produce a lifestyle approach to social policy, the 
cumulative outcome of research in cancer epidemiology could equate positive 
implications to population health. 
It is important to acknowledge the promise of the holistic approach to improving 
health behaviors through health literacy among vulnerable groups that were found to be 
an increased risk of developing PC. Complimentary to the statistical outcome of this 
dissertation, Clouston, Manganello, and Richards, (2017) found that women have higher 
health literacy than men. Moreover, given that an increase in age was associated with the 
odds of developing PC/CTSG-A, a holistic approach should be focused not only on the 
adults but also the younger members of families and communities (Clauston et al., 2017). 
According to Kumar et al. (2012), the attainment of the highest possible standard of 
health depends on a comprehensive, holistic approach which goes beyond the traditional 
curative care, involving communities, health providers, and other stakeholders. The 
challenges due to the changing scenarios such as demographic and epidemiological 
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transition, proven by the statistical outcome of this dissertation, amplifies the need for 
newer, innovative approaches that are multisectoral, adequately funded, evidence-based 
health promotion program with community participation. The global acceptance that 
health and social well-being are determined by many factors which are outside the health 
system that requires modification of the complex socioeconomic determinants of health, 
targeting the complex socioeconomic and cultural changes at family and community 
levels (Kumar and Preetha, 2012). 
The argument on the gene-environment interaction paradigm to genome-wide 
studies in relation to the development of a public issue was discussed in the 2014 study of 
Boardman et al., highlighting the importance of integrating social and genetic 
perspectives in enhancing findings for both biologically and socially focused research 
such as the causality of active and passive smoke exposure to lifetime risk of a fetus to 
develop a lethal disease like PC. For decades, behavior geneticists have been working to 
disentangle the genomic component of family risk from the social and behavioral 
component. According to Boardman et al., understanding the genomic component in 
combination with specific environmental contexts could provide the pertinent 
information about an individual’s likelihood of exhibiting a particular behavior at a given 
time, critical not only to social and genetic epidemiologists, but to the understanding of 
the causes, modifiable behavioral risk and adjustable predictors in the development of the 
disease. New evidence for genetic influences on most health behaviors, new statistical 
methods, and new genetic data sources could help confirm the significance of 
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environmental influences on individual’s genetic composition that could be contingent on 
the social environment in which one resides, works, and plays.  
The mutually advantageous conjunction of viewing positive social change in 
cancer epidemiology beyond genetics and social inequalities, the continued technical 
advancement to gauge host resistance at a molecular level before the onset of disease and 
within the healthy social ecology will lead to human vitality and physiological resilience 
(Cole, 2013). Moreover, in combination with the conceptual advances of a network-level 
metagenomic approach to people’s health, Cole (2013) emphasized its weight in 
accelerating the ongoing transformation of public health from a disease-reactive model to 
a more proactive and health-centered approach. While genome-wide analysis can 
hypothesize links to environmental sensitivity via biologically plausible networks 
(Duncan et al. 2010), positive social change is critical to the continued interest and 
openness in knowing about one’s genetic makeup that holds sufficient information 
enough to construct a priori disease-specific genetic profiles (Boardman et. al, 2014). 
Recommendations for Action 
Cancer is a growing global problem and is increasing in the proportion of the 
burden among low income and middle-income countries. The pattern can be blamed on 
demographic change and to transition in risk factors, but can be preventable by present 
knowledge of risk factors. In early 2000, PC incidence rates have been approximately 
stable in many European countries, overall trends in USA, Japan, and Australia are likely 
to improve in the next future with more favorable trends among young adults from 30 to 
49 years old (Bosetti et al., 2012b). Pancreatic cancer has the lowest 5-year relative 
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survival rate, and treatment for metastatic pancreatic cancer are minimally effective. Ma, 
Siegel, & Jemal (2013) noted that the complex patterns about death rate trends for 
pancreatic cancer remain unexplained by known risk factors. Given that there are only 
20% of patients diagnosed with the disease are eligible for surgical resection (Spanknebel 
& Conlon, 2000); it is paramount to rationalize the importance of the development of 
public health policies designed in lowering the economic burden of the disease. Money 
saved from reducing the overall economic burden of the disease could open up resources 
and funding allocation to pursue other public health projects for the better good of the 
many. 
Environmental tobacco smoke (ETS) is an example of environmental exposure 
that has been associated with an array of adverse effects on health. Secondhand smoke, 
referred to as ETS, contains many of the same carcinogenic compounds as the 
mainstream smoke inhaled by active smokers (World Health Organization, International 
Agency for Research on Cancer, 2004; Bao et al., 2009). Under the lens of public health, 
quitting smoking could decrease the incidence of PC, by protecting vulnerable members 
of the population. The rapid uptake and use of new health information among vulnerable 
groups, and access to health-enhancing treatment and technologies will be dependent 
upon the development and implementation of public health policies that include equitable 
allocation of resources to every enclave of the community. While the past and current 
research could help continue the improvement of the accuracy of passive smoking 
measurement, it is critical for the continuance of applying the exposome concept to 
environmental health problems. Research outcomes that help the drafting of amendments 
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to policies and approaches, built on existing policies such as cigarette labeling acts, 
smoking bans, and distribution of cessation tools will not only improve mortality level of 
the disease but population health as a whole.  
One of the greatest challenges and opportunities for 2016 is to intensify the 
implementation of evidence-based path-breaking interventions in modifying major risk 
factors for chronic diseases such pancreatic cancer beyond genetics and social 
inequalities. According to Halpin et al. (2010), delivering interventions at the level of 
society using the paradigm of the New Public Health can change the environment, and 
individual behaviors through public health policy, and focus beyond genetics and social 
inequalities. It is critical to acknowledge the burden of PC and the assessment of the 
current state of research on this issue, shedding light on the critical significance of 
environmental epidemiology in protecting vulnerable subgroups of populations from 
environmental hazards and its causal association on induction and promotion of 
pancreatic cancer. The burden of chronic diseases such PC is often ignored on the public 
agendas at both the individual and community level, albeit most public health 
interventions focus on induction and promotion (Haplin et al., 2010). While the 
correlation of smoking is statistically significantly weak in this dissertation, the biggest 
single cause of cancer is tobacco use. Therefore, it is paramount to embrace the concept 
of precision medicine in integrating molecular pathology, epidemiology, and social 
science.  
The evolving transdisciplinary field of molecular pathological epidemiology 
(MPE), could better connect the dots of the pathopoiesis mechanism of smoking and 
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shared genes in pancreatic cancer, as well as integrate molecular analysis into social 
epidemiology for deeper insights on social influences on pathogenic processes (Nishi et 
al., 2016). According to Colditz, Wolin, and Gehlert (2012), better implementation of 
lessons learned in this dissertation could contribute to achieving maximal possible cancer 
prevention, to counter the projected doubling of cancer cases diagnosed by 2050 
(Edwards et al., 2002). While molecular window into the body could help guide public 
health interventions and social policies to more proactively address the general host 
resistance factors that seem to precipitate multiple diseases (Miller, Chen, & Cole, 2009), 
lessons learned from studies that link specific gene expression profiles to disease 
vulnerability could help gauge the toxicity of various social or geographic environments 
or the success of public policies and interventions (Cole, 2013). As some researchers 
argue the complexity of exploring the assumption that smoking and family history, both 
commonly track together in the same family and differentiating the genetic component 
from the carcinogen exposure may be difficult or even impossible without exploring its 
molecular window, or limited access to established registry data, it is important to 
consider revising current BRFSS cancer survivorship module. Such revision could open 
the opportunity for an inferential risk and cancer-specific profiles. Furthermore, an 
additional module on sleeping habits and patterns in Expanded BRFSS could connect the 
dot on its association with higher body weight or obesity that is known to be a behavioral 
risk factor in cancer evolution (Donohoe, Lysaght, O’Sullivan, & Reynolds, 2017). 
The cloud created by the present administration’s goals of the “FY 2018 skinny 
budget” that was widely condemned by scientists and public health advocates is the deep 
102 
 
cuts in medical research and health care (Lewis-Burke Associates, 2017). This initial 
funding blueprint would weaken public health ad nauseam, as much of the health safety 
net formed by the Department of Health and Human Services, the Centers for Medicare 
and Medicaid Services, the Centers for Disease and Prevention (CDC), and the National 
Institutes of Health (NIH). What can we do to offset the ramifications of the Trump 
budget? The deplorable truth is that if this budget were enacted, will not only result in 
cancers and diseases going undetected, but the future of scientists and academics who 
work so hard to reverse mortality rate, and economic burden. Infectious diseases, and 
current public health issues that include bioterrorism, and violent radicalization will not 
be deterred by a proposed enhanced wall in our borders.  
Recommendations for Future Research 
One of the major obstacles confronting funding research and public health 
projects is the failure to connect the dots between the significance of continued 
investigation on innovative cancer management and raising general public awareness on 
cancer problem and control. Improving the future of individuals diagnosed with 
pancreatic cancer (PC) through the concerted efforts of policymakers, public health 
professionals, clinicians and scientists, the Recalcitrant Cancer Research Act of 2012 lays 
the foundation for a heightened focused on further development and use of prevention, 
screening and therapeutic strategy (Rahib et al., 2014). Introduced initially as the 
Pancreatic Cancer Research and Education Act, the Recalcitrant Cancer Research Act 
was signed into law as part of the National Defense Authorization Act on January 2, 
2013, through broad bi-partisan and bi-cameral support (The pancreatic cancer action 
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network, 2013). The genuine progress against PC as recalcitrant cancer warrants strategic 
direction and guidance on the continued understanding, development of efficient early 
detection strategy and identifying therapeutic targets that could stem the tide of its 
growing economic burden.  
Continued research on the association between passive smoking exposure and the 
disease, as well as early shared exposure of these predictors, are critical to broadening the 
understanding of its significance to lifetime increased risk. The focus on obtaining a 
larger number of endpoints, it is paramount for future research to combine more cohorts 
to have a stronger and standardized sampling that yields a statistically significant 
assessment of predictors associated with pancreatic cancer. A synergy begets by 
outcomes research and epidemiology can provide unique and compelling insights on the 
significance of interventions designed to improve the quality and effectiveness of care in 
populations. It is important to acknowledge the need for continued research to establish a 
meaningful risk prediction models that could be practically applied in clinical settings to 
raise the accuracy of predicting the potential for PC. Given that surgical resection 
procedure is the only treatment approach that could improve survival rate, establishing a 
high-risk prediction model using novel early identification protocol of pre-malignant 
lesions and molecular profiling, as part of a personalized therapeutic approach and 
standardized methods of early detection, and prevention.  
Pancreatic cancer (PC) involves both genetic and environmental factors, and like 
any other human diseases, PC is complex and multifactorial that has the greatest burden 
on society. According to Bookman et al. (2011), the development of high-density 
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genotyping platforms has allowed investigators to screen hundreds of thousands of 
genetic variants to test for associations with disease (p.2). Hindorff et al. (2011) asserted 
that to date, Genome Wide Association Studies (GWAS) have identified over 900 
statistically significant findings in various diseases and conditions. While there is much 
work still needed to develop practical, ethical, useful policies on GWAS, it is imperative 
to embolden researchers in the continued exploration of genetic and environmental 
interactions associated with PC and CTSG-A that may identify additional risk factors or 
what proportion of cancer induction, promotion, expression is induced by inherited 
predisposition or combination of shared environmental, and biodemographic factors. 
Future research on the predictive value of whole-genome sequencing (WGS) in the 
healthy population is critical on the hypothesis of meaningful information that sheds light 
on individual differences in environmental sensitivity that will give summary information 
across a number of different loci may prove to be useful (Boardman et al., 2014; Lindor, 
Thibodeau, & Burke, 2017). The mechanism(s) through which environmental, genetic, 
biodemographic interaction (EGBI) with the particular focus on the effect of tobacco 
carcinogens as a shared environmental factor to shared genetic footprints in family cancer 
history (FCH) or its combined role remains unknown. Henceforth, it is critical to explore 
their correlation in future research, satisfying the sense of urgency for novel and 
innovative therapeutics. As stated by Lu et al. (2017), continued understanding of 
genomic variations in PC is crucial in providing an avenue for precision medicine. As 
emphasized by Lu et al. (2017), sustained understanding of genomic variations in PC is 
vital in providing an avenue for precision medicine. It is essential to highlight the 
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significance of these studies in providing fundamental knowledge for new and effective 
treatment strategies. 
Conclusion 
Pancreatic cancer has the global ranking of 13 as the most common cause of 
cancer and represents the 7th most frequent cause of cancer death, and accounts for about 
3% of all cancers in the US with cancer mortality of 7% (American Cancer Society, Inc., 
2016). These statistics justify the intent of this dissertation to determine whether there is 
existence or absence of correlation between tobacco use, gender, and age in the 
etiopathogenesis of PC and other cancer types with shared-gene association (CTSG-A), 
with the intent of advancing the existing body of knowledge on environmental, genetic 
and biodemographic interactions (EGBIs) in cancer evolution. While the results of this 
study supported the null hypotheses that smoking has no correlation with the prevalence 
of PC and CTSG-A, both gender and age are statistically significant predictors that 
supports the need for future research on the modification effect of shared environmental 
factors and etiopathogenic role of biodemographic factors (age, gender, race, 
socioeconomic status) in cancer evolution.  
Ab-initio studies have established that family history of PC can manifest due to 
genetic factors and shared environmental factors. The scientific perspective of this 
dissertation, current, and past studies are parallel to Albert Einstein’s concept of “natura 
naturans”—everything is connected. In this dissertation, the assumption that 
P16(CDKN2A), PRSS1, BRCA1, STK11, LKB1, bMLH1, and bMSH2 are correlated 
with the development of the disease is mathematically or statistically correct and deserves 
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further investigation. The results provided the rationale for further research on the 
pathopoiesis mechanism of shared environmental and genetic factors that are responsible 
for pancreatic cancer and other CTSG-A evolution. Such molecular window could initiate 
evidence-based discussions on the urgent need to revise or improve the BRFSS cancer 
survivorship module. While our understanding of the molecular events underlying multi-
step carcinogenesis in PC has steadily increased (Lu et al., 2017), according to “Analysis 
of the President’s FY 2018 Budget Request for Federal Research, Health, and Higher 
Education Programs” (2017), “the current administration’s budget blueprint would reduce 
funding for Chronic Disease Prevention and Promotion at the CDC by about $164 
million” (p. 27). For decades, the federal government has committed to the advancement 
of science and population health. It is not our duty to participate in a partisan debate, but 
rather protect our long history of closing the gap to equal access to quality health care 
through evidence-based studies. It is important to recognize the much-needed focus on 
policies that will promote broader population health, as well as potential public policies 
that could improve health behaviors easier, particularly for those who belong to 
vulnerable, high-risk groups. The assumption of the association of modifiable risk factors 
and CPG using the unified paradigm of cancer causation, or the probability of precise 
measurement of a risk factor that wakes up dormant mutated cancer genes using 
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Genetic Alterations in Common Neoplasms of the Pancreas 
TUMOR TYPE GENE(S) PREVALENCE OF 
THE ALTERATION 
COMMENT 
Acinar cell carcinoma APC 15%  
 Acinar cell carcinoma 5%  
Invasive ductal 
Adenocarcinoma 
KRAS 95% KRAS mutations occur 
early, and KRAS 
mutations may be a 
target for early 
detection 
 p16/CDKN2A 95%  
 TP53 75%  
 SMAD4 55% SMAD4 loss 
associated with poor 
prognosis and 
widespread disease 
 MLL3, TGFBR2, 
FBXW7, ARID1A, 
AIRID2, and ATM 




IPMN KRAS 80%  
 RNF43 75% RNF43 is a marker of 
mucin-producing 
tumors because it is 
present in both 
IPMNs and MCNs 
 GNAS 60% GNAS is a marker of 
IPMNs. GNAS 
and/or KRAS 
mutations are present 
in >95% of all IPMNs 
 p16/CDKN2A Varies dependent on 
histologic grade 
 
 TP53 Varies dependent on 
histologic grade 
Associated with higher 
grade lesions 
 SMAD4 Varies dependent on 
histologic grade 
Associated with higher 
grade lesions 
 PIK3CA 10%  
MCN KRAS 75%  
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 RNF43 40% RNF43 is a marker of 
mucin-producing 
tumors, present in 
IPMNs and MCNs 
 p16/CDKN2A Varies dependent on 
histologic grade 
 
 TP53 Varies dependent on 
histologic grade 
Associated with higher 
grade lesions 
 SMAD4 Varies dependent on 
histologic grade 
Associated with higher 
grade lesions 
Pancreatoblastoma Imprinted region 
on chromosome 11 
85% Same region is targeted 
in hepatoblastoma 




 APC 10%  
PanNET MEN1 45%  
 DAXX or ATRX 45% Associated with ALT+ 
 TSC2, PTEN, and 
PIK3CA (mTOR 
pathway genes) 
15% Potentially targetable 
therapeutically 
with everolimus 
SCN VHL 50% Among the cystic 
tumors of the pancreas, 




95% Immunolabeling for 
beta-catenin is 
useful diagnostically 
ALT+ indicates an alternative lengthening of telomeres; IPMN, intraductal papillary 
mucinous neoplasm; MCN, mucinous cystic neoplasm; PanNET, pancreatic 
neuroendocrine tumor; SCN, serous cystic neoplasm; SPN, solid-pseudopapillary 
neoplasm. 
Note: Adapted from “Recent progress in pancreatic cancer” by Wolfgang et al., 2013, 
CA: a cancer journal for clinicians, American Cancer Society, 63(5), p. 327. Copyright 





Cancer (CA) Types Surveyed During the 2014 BRFSS, 
Five-States Cancer Survivorship Module  
Frequency Percent Valid Percent 
Valid 
 
Breast Cancer 1178 16.4 16.4 
Cervical Cancer 340 4.7 4.7 
Endometrial Cancer 178 2.5 2.5 
Ovarian Cancer 104 1.5 1.5 
Cancer of the Head and Neck 20 .3 .3 
Oral Cancer 22 .3 .3 
Pharyngeal Cancer 45 .6 .6 
Thyroid Cancer 131 1.8 1.8 
Cancer of the Larynx 5 .1 .1 
Colorectal Cancer 337 4.7 4.7 
Esophageal Cancer 13 .2 .2 
Liver Cancer 19 .3 .3 
Pancreatic Cancer 12 .2 .2 
Rectal Cancer 31 .4 .4 
Cancer of the Stomach 13 .2 .2 
Hodgkin’s Lymphoma 61 .9 .9 
Leukemia 73 1.0 1.0 
Non-Hodgkin’s Lymphoma 77 1.1 1.1 
Prostate Cancer 613 8.6 8.6 
Testicular Cancer 25 .3 .3 
Melanoma 964 13.4 13.4 
Other skin cancer 2183 30.5 30.5 
Lung Cancer 137 1.9 1.9 
Bladder Cancer 129 1.8 1.8 
Renal Cancer 100 1.4 1.4 
Cancer of the Bone 38 .5 .5 
Brain Cancer 16 .2 .2 
Neuroblastoma 5 .1 .1 
Other 300 4.2 4.2 






CA Type with SG-A Before Data 
Cleaning and Re-coding Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Other CA Types with 0-
Known SG-A 
1312 43.7 43.7 43.7 
Breast Cancer 473 15.8 15.8 59.4 
Endometrial Cancer 84 2.8 2.8 62.2 
Ovarian Cancer 40 1.3 1.3 63.6 
Cancer of the Head and 
Neck 
8 .3 .3 63.8 
Colorectal Cancer 142 4.7 4.7 68.6 
Esophageal Cancer 6 .2 .2 68.8 
Pancreatic Cancer 6 .2 .2 69.0 
Cancer of the Stomach 5 .2 .2 69.1 
Leukemia 27 .9 .9 70.0 
Melanoma 460 15.3 15.3 85.3 
Lung Cancer 70 2.3 2.3 87.7 
Bladder Cancer 49 1.6 1.6 89.3 
Renal Cancer 45 1.5 1.5 90.8 
Brain Cancer 7 .2 .2 91.0 
Prostate Cancer 256 8.5 8.5 99.6 
Osteosarcoma (Bone) 13 .4 .4 100.0 







Prev1*Respondents Gender Crosstabulation 
 
Respondents Gender 
Total Male Female 
Prev1 BRCA1/STK11/LKB1/bML
H1/bMSH2 
Count 322 678 1000 
Expected Count 409.2 590.8 1000.0 
P16(CDKN2A)/PRSS1 Count 370 321 691 
Expected Count 282.8 408.2 691.0 
Total Count 692 999 1691 












Pearson Chi-Square 77.013a 1 .000   
Continuity Correctionb 76.133 1 .000   
Likelihood Ratio 76.990 1 .000   
Fisher’s Exact Test    .000 .000 
Linear-by-Linear 
Association 
76.968 1 .000 
  
McNemar Test    .c  
N of Valid Cases 1691     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 282.77. 
b. Computed only for a 2x2 table 





Prev1*Three Age Group Crosstabulation 
Table 13A: Prev1 * Three Age Group Crosstabulation 
 
Three Age Group 
Total <51 52-69 70> 
Prev1 BRCA1/STK11/LKB1/bML
H1/bMSH2 
Count 62 369 569 1000 
Expected Count 74.5 389.7 535.8 1000.0 
P16(CDKN2A)/PRSS1 Count 64 290 337 691 
Expected Count 51.5 269.3 370.2 691.0 
Total Count 126 659 906 1691 








Pearson Chi-Square 12.876a 2 .002 
Likelihood Ratio 12.818 2 .002 
Linear-by-Linear 
Association 
12.869 1 .000 
McNemar-Bowker Test . . .b 
N of Valid Cases 1691   
a. 0 cells (.0%) have expected count less than 5. The minimum 
expected count is 51.49. 





Prev1*Four-Level Smoking Status Crosstabulation 
 















Count 66 19 362 553 1000 
Expected 
Count 




Count 58 17 293 323 691 
Expected 
Count 
50.7 14.7 267.7 358.0 691.0 
Total Count 124 36 655 876 1691 
Expected 
Count 






 Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 12.228a 3 .007 
Likelihood Ratio 12.229 3 .007 
Linear-by-Linear Association 9.282 1 .002 
McNemar-Bowker Test . . .b 
N of Valid Cases 1691   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 14.71. 




Prev2*Respondents Gender Crosstabulation 
 
Respondents Gender 
Total Male Female 
Prev2 P16(CDKN2A)/PRSS1/bM
LH1/bMSH2 
Count 434 488 922 
Expected Count 377.3 544.7 922.0 
BRCA1/STK11/LKB1 Count 258 511 769 
Expected Count 314.7 454.3 769.0 
Total Count 692 999 1691 








































Exact Sig. (1-sided) 
Pearson Chi-Square 31.709a 1 .000   
Continuity Correctionb 31.152 1 .000   
Likelihood Ratio 31.926 1 .000   
Fisher’s Exact Test    .000 .000 
Linear-by-Linear 
Association 
31.690 1 .000 
  
McNemar Test    .c  
N of Valid Cases 1691     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 314.69. 
b. Computed only for a 2x2 table 





Prev2*Three Age Group Crosstabulation 
 
Three Age Group 
Total <51 52-69 70> 
Prev2 P16(CDKN2A)/PRSS1/
bMLH1/bMSH2 
Count 82 366 474 922 
Expected Count 68.7 359.3 494.0 922.0 
BRCA1/STK11/LKB1 Count 44 293 432 769 
Expected Count 57.3 299.7 412.0 769.0 
Total Count 126 659 906 1691 








Pearson Chi-Square 7.714a 2 .021 
Likelihood Ratio 7.829 2 .020 
Linear-by-Linear 
Association 
6.644 1 .010 
McNemar-Bowker Test . . .b 
N of Valid Cases 1691   
a. 0 cells (.0%) have expected count less than 5. The minimum 
expected count is 57.30. 





Prev2*Four-Level Smoking Status Crosstabulation 
 















Count 74 20 381 447 922 
Expected 
Count 
67.6 19.6 357.1 477.6 922.0 
BRCA1/ST
K11/LKB1 
Count 50 16 274 429 769 
Expected 
Count 
56.4 16.4 297.9 398.4 769.0 
Total Count 124 36 655 876 1691 
Expected 
Count 








Pearson Chi-Square 9.171a 3 .027 
Likelihood Ratio 9.186 3 .027 
Linear-by-Linear 
Association 
6.434 1 .011 
McNemar-Bowker Test . . .b 
N of Valid Cases 1691   
a. 0 cells (.0%) have expected count less than 5. The minimum 
expected count is 16.37. 
b. Computed only for a PxP table, where P must be greater than 1. 
 
